10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

MARK ONE

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the Quarterly Period ended March 31, 2023;

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from ________ to ________

ZION OIL & GAS, INC.

(Exact name of registrant as specified in its charter)

Delaware	20-0065053
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)
12655 N Central Expressway, Suite 1000, Dallas, TX	75243
(Address of principal executive offices)	Zip Code

(214) 221-4610

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒

As of May 9, 2023, Zion Oil & Gas, Inc. had outstanding 540,313,673 shares of common stock, par value $0.01 per share.

INDEX PAGE

	Page
PART I — FINANCIAL INFORMATION
Item 1 – Financial Statements – Unaudited
Consolidated Condensed Balance Sheets – March 31, 2023 and December 31, 2022	1
Consolidated Condensed Statements of Operations for the three months ended March 31, 2023 and 2022	2
Consolidated Condensed Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2023 and 2022	3
Consolidated Condensed Statements of Cash Flows for the three months ended March 31, 2023 and 2022	4
Notes to Consolidated Condensed Financial Statements	6
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	33
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	41
Item 4 – Controls and Procedures	41
PART II — OTHER INFORMATION
Item 1 – Legal Proceedings	42
Item 1A – Risk Factors	42
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	42
Item 3 – Defaults upon Senior Securities	42
Item 4 – Mine Safety Disclosures	42
Item 5 – Other Information	42
Item 6 – Exhibits	42
Exhibit Index	43
SIGNATURES	44

i

Zion Oil & Gas, Inc.

Consolidated Condensed Balance Sheets as of

	March 31, 2023			December 31, 2022
	US$ thousands			US$ thousands
Current assets	(Unaudited)
Cash and cash equivalents		799			1,735
Fixed short term bank and escrow deposits – restricted		1,360			1,379
Prepaid expenses and other current assets		581			600
Other deposits		155			483
Governmental receivables		26			267
Other receivables		139			143
Total current assets		3,060			4,607
Unproved oil and gas properties, full cost method (see Note 4)		16,057			15,889
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $1,645 and $1,455 (see note 2I)		6,080			6,281
Property and equipment, net of accumulated depreciation of $657 and $647		102			112
		6,182			6,393
Right of Use Lease Assets (see Note 5)		135			202
Other assets
Assets held for severance benefits		425			424
Total other assets		425			424
Total assets		25,859			27,515
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable		2,017			2,147
Lease obligation – current (see Note 5)		125			196
Asset retirement obligation		571			571
Accrued liabilities		495			1,032
Total current liabilities		3,208			3,946
Long-term liabilities
Lease obligation – non-current (see Note 5)		12			12
Provision for severance pay		461			457
Total long-term liabilities		473			469
Total liabilities		3,681			4,415
Commitments and contingencies (see Note 6)
Stockholders’ equity
Common stock, par value $.01; Authorized: 800,000,000 shares at March 31, 2023: Issued and outstanding: 533,713,261 and 524,231,493 shares at March 31, 2023 and December 31, 2022, respectively		5,337			5,242
Additional paid-in capital		297,582			296,460
Accumulated deficit		(280,741	)		(278,602	)
Total stockholders’ equity		22,178			23,100
Total liabilities and stockholders’ equity		25,859			27,515

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

1

Zion Oil & Gas, Inc.

Consolidated Condensed Statements of Operations (Unaudited)

	For the three months ended
	March 31,
	2023			2022
	US$ thousands			US$ thousands
	(Unaudited)			(Unaudited)
General and administrative		1,503			1,435
Other		583			711
Post impairment of unproved oil and gas properties		45			-
Loss from operations		(2,131	)		(2,146	)
Other expense, net
Foreign exchange (loss)		(2	)		(9	)
Financial (expenses), net		(6	)		(11	)
Loss, before income taxes		(2,139	)		(2,166	)
Income taxes		-			-
Net loss		(2,139	)		(2,166	)
Net loss, per share of common stock
Basic and diluted (in US$)		(0.004	)		(0.005	)
Weighted-average shares outstanding
Basic and diluted (in thousands)		531,023			404,817

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

2

Zion Oil & Gas, Inc.

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited)

For the three months ended March 31, 2023 

	Common Stock				Additional paid-in		Accumulated
	Shares		Amounts		Capital		deficit			Total
	thousands		US$ thousands		US$ thousands		US$ thousands			US$ thousands
Balances as of December 31, 2022		524,231		5,242		296,460		(278,602	)		23,100
Funds received from sale of DSPP units and shares and exercise of warrants		9,357		94		698		—			792
Funds received from option exercises		125		1		7		—			8
Value of options granted to employees, directors and others as non-cash compensation		—		—		417		—			417
Net loss		—		—		—		(2,139	)		(2,139	)
Balances as of March 31, 2023		533,713		5,337		297,582		(280,741	)		22,178

* Less than one thousand.

For the three months ended March 31, 2022 

	Common Stock				Additional paid-in		Accumulated
	Shares		Amounts		Capital		deficit			Total
	thousands		US$ thousands		US$ thousands		US$ thousands			US$ thousands
Balances as of December 31, 2021		364,324		3,643		277,258		(223,525	)		57,376
Funds received from sale of DSPP units and shares and exercise of warrants		102,219		1,022		10,405		—			11,427
Funds received from option exercises		50		1		—		—			1
Value of options granted to employees, directors and others as non-cash compensation		—		—		215		—			215
Net loss		—		—		—		(2,166	)		(2,166	)
Balances as of March 31, 2022		466,593		4,666		287,878		(225,691	)		66,853

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

3

Zion Oil & Gas, Inc.

Consolidated Condensed Statements of Cash Flows (Unaudited)

	For the three months ended March 31,
	2023			2022
	US$ thousands			US$ thousands
	(Unaudited)			(Unaudited)
Cash flows from operating activities
Net loss		(2,139	)		(2,166	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		200			195
Cost of options issued to employees, directors and others as non-cash compensation		417			208
Post impairment of unproved oil and gas properties		45			-
Change in assets and liabilities, net:
Other deposits		328			12
Prepaid expenses and other		19			(575	)
Governmental receivables		241			562
Lease obligation – current		(71	)		(34	)
Lease obligation – non current		-			(40	)
Right of use lease assets		67			64
Other receivables		4			107
Severance payable, net		3			-
Accounts payable		26			(331	)
Accrued liabilities		(57	)		(93	)
Net cash used in operating activities		(917	)		(2,091	)
Cash flows from investing activities
Acquisition of property and equipment		-			(12	)
Acquisition of drilling rig and related equipment		-			(122	)
Investment in unproved oil and gas properties		(838	)		(3,665	)
Net cash used in investing activities		(838	)		(3,799	)
Cash flows from financing activities
Proceeds from exercise of stock options		8			1
Proceeds from issuance of stock and exercise of warrants		792			9,427
Net cash provided by financing activities		800			9,428
Net (decrease)/increase in cash, cash equivalents and restricted cash		(955	)		3,538
Cash, cash equivalents and restricted cash – beginning of period		3,114			5,952
Cash, cash equivalents and restricted cash – end of period		2,159			9,490
Supplemental schedule of cash flow information
Non-cash investing and financing activities:
Non-cash equity receivables		-			2,000
Unpaid investments in oil & gas properties		1,515			1,130
Capitalized convertible bond interest attributed to oil and gas properties		-			-
Cost of options issued to employees attributed to oil and gas properties		-			7

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

4

Cash, cash equivalents and restricted cash, are comprised as follows:

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Cash and cash equivalents		799		1,735
Restricted cash included in fixed long-term bank deposits		1,360		1,379
		2,159		3,114

5

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 1 - Nature of Operations, Basis of Presentation and Going Concern

A. Nature of Operations 

Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 23 years of oil & gas exploration in Israel. As of March 31, 2023, the Company has no revenues from its oil and gas operations.

Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company.

On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect.

Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel.

Exploration Rights/Exploration Activities

New Megiddo License 428 (“NML 428”)

The New Megiddo License 428 (“NML 428”) was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

Prior to the filing of this Quarterly Report, we received initial administrative approval from various departments within the Israel Ministry of Energy which puts us in an excellent position to obtain final approval of our license.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

We are focusing on finalizing the technical and operational preparations for our re-entry of the MJ-01 well.

6

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 1 - Nature of Operations, Basis of Presentation and Going Concern (cont’d)

B. Basis of Presentation 

The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the year ending December 31, 2023 or for any other subsequent interim period.

C. Going Concern 

The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. 

The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the three months ended March 31, 2023, the Company incurred a net loss of approximately $2.2 million and had an accumulated deficit of approximately $281 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the financials were issued.

To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty 

7

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 2 - Summary of Significant Accounting Policies

A. Net Loss per Share Data 

Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share as the inclusion of 57,997,687 and 23,144,603 Common Stock equivalents in 2023, and 2022 respectively, would be anti-dilutive.

B. Use of Estimates 

The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

C. Oil and Gas Properties and Impairment 

The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method.

8

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 2 - Summary of Significant Accounting Policies (cont’d)

The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $45,615,000.

During the three months ended March 31, 2023, the Company recorded post-impairment charges of $45,000. During the three months ended March 31, 2022, the Company did not record any post-impairment charges.

Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $16,057,000 and $15,889,000 as of March 31, 2023 and December 31, 2022, respectively.

D. Fair Value Measurements 

The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At March 31, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.  

9

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 2 - Summary of Significant Accounting Policies (cont’d)

E. Stock-Based Compensation 

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

F. Warrants 

In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity.

G. Related parties 

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged.

Zion did not have any related party transactions for the periods covered in this report.

10

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 2 - Summary of Significant Accounting Policies (cont’d)

H. Recently Adopted Accounting Pronouncements 

In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

 In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. Zion adopted ASU 2021-08 in the first quarter of 2023. The adoption of this ASU did not have a material impact on our consolidated financial statements; the impact in future periods will be dependent upon the contract assets acquired and contract liabilities assumed in any future business combinations.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a roll forward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for roll forward information, which is effective for fiscal years beginning after December 15, 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

Other Recent Accounting Pronouncements

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow.

11

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 2 - Summary of Significant Accounting Policies (cont’d)

I. Depreciation and Accounting for Drilling Rig and Related Equipment 

On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021.

The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet.

In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion will depreciate the rig on a straight-line basis.

Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed.

It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly.

See the table below for a reconciliation of the rig-related activity during the quarter ended March 31, 2023:

I-35 Drilling Rig & Associated Equipment:

	Three-month period ended March 31, 2023
	I-35 Drilling Rig			Rig Spare Parts			Other Drilling Assets			Total
	US$ thousands			US$ thousands			US$ thousands			US$ thousands
December 31, 2022		5,225			619			437			6,281
Asset Additions		-			-			-			-
Asset Depreciation		(159	)		-			(32	)		(191	)
Asset Disposals for Self-Consumption		-			(10	)		-			(10	)
March 31, 2023		5,066			609			405			6,080

12

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity

The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 400,000,000 shares to 800,000,000 shares, effective June 9, 2021.

A. 2021 Omnibus Incentive Stock Option Plan

Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock.

The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions.

The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant.

During the three months ended March 31, 2023, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

i. Options to purchase 175,000 shares of Common Stock to five senior officers and one staff member at an exercise price of $0.0615 per share. The options vested upon grant and are exercisable through January 4, 2033. The fair value of the options at the date of grant amounted to approximately $9,000.

ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $1,500.

13

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

During the three months ended March 31, 2022, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

i. Options to purchase 175,000 shares of Common Stock to six senior officers and one staff member at an exercise price of $0.1529 per share. The options vested upon grant and are exercisable through January 4, 2032. The fair value of the options at the date of grant amounted to approximately $22,000.

ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $4,000.

iii. Options to purchase 300,000 shares of Common Stock to one senior officer and one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $39,000. 

iv. Options to purchase 200,000 shares of Common Stock one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $29,000. 

v. Options to purchase 1,600,000 shares of Common Stock to five senior officers and four staff members at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $209,000, and will be recognized during the years 2022 and 2023.

vi.	Options to purchase 1,400,000 shares of Common Stock to seven board members, at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $182,000, and will be recognized during the years 2022 and 2023.
vii.	Options to purchase 160,000 shares of Common Stock to four staff members, at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 17, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $23,000.
viii.	Options to purchase 200,000 shares of Common Stock to six staff members at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $26,000, and will be recognized during the years 2022 and 2023.
ix.	Options to purchase 40,000 shares of Common Stock to two consultants at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $5,000, and will be recognized during the years 2022 and 2023.

14

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

B. Stock Options 

The stock option transactions since January 1, 2023 are shown in the table below:

	Number of shares			Weighted Average exercise price
				US$
Outstanding, December 31, 2022		26,391,250			0.30
Changes during 2023 to:
Granted to employees, officers, directors and others		200,000			0.06
Expired/Cancelled/Forfeited		-			-
Exercised		(125,000	)		0.06
Outstanding, March 31, 2023		26,466,250			0.30
Exercisable, March 31, 2023		14,901,250			0.40

15

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

The following table summarizes information about stock options outstanding as of March 31, 2023:

Shares underlying outstanding options (non-vested)								Shares underlying outstanding options (fully vested)
Range of exercise price		Number outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price		Range of exercise price		Number Outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price
US$						US$		US$						US$
	0.15		6,410,000		9.05		0.15		0.01		10,000		0.62		0.01
	0.18		5,155,000		9.49		0.18		0.01		5,000		1.20		0.01
	—		—		—		—		0.01		20,000		3.17		0.01
	—		—		—		—		0.01		130,000		3.75		0.01
	—		—		—		—		0.01		50,000		3.76		0.01
	—		—		—		—		0.01		60,000		4.04		0.01
	—		—		—		—		0.01		200,000		4.13		0.01
	—		—		—		—		0.01		40,000		4.50		0.01
	—		—		—		—		0.01		70,000		4.75		0.01
	—		—		—		—		0.01		25,000		4.76		0.01
	—		—		—		—		0.01		30,000		4.91		0.01
	—		—		—		—		0.01		4,000		5.01		0.01
	—		—		—		—		0.01		25,000		5.77		0.01
	—		—		—		—		0.01		35,000		6.46		0.01
	—		—		—		—		0.01		150,000		6.63		0.01
	—		—		—		—		0.01		35,000		6.76		0.01
	—		—		—		—		0.01		75,000		7.76		0.01
	—		—		—		—		0.01		200,000		8.14		0.01
	—		—		—		—		0.01		300,000		8.29		0.01
	—		—		—		—		0.01		10,000		8.42		0.01
	—		—		—		—		0.01		500,000		8.76		0.01
	—		—		—		—		0.01		55,000		8.80		0.01
	—		—		—		—		0.01		960,000		9.04		0.01
	—		—		—		—		0.01		75,000		9.37		0.01
	—		—		—		—		0.01		10,000		9.42		0.01
	—		—		—		—		0.01		795,000		9.48		0.01
	—		—		—		—		0.01		25,000		9.76		0.01
	—		—		—		—		0.06		50,000		9.76		0.06
	—		—		—		—		0.14		240,000		8.80		0.14
	—		—		—		—		0.15		25,000		8.76		0.15
	—		—		—		—		0.15		3,200,000		9.00		0.15
	—		—		—		—		0.16		340,000		2.69		0.16
	—		—		—		—		0.16		75,000		6.69		0.16
	—		—		—		—		0.18		25,000		2.67		0.18
	—		—		—		—		0.24		25,000		9.34		0.24
	—		—		—		—		0.24		118,000		9.37		0.24
	—		—		—		—		0.25		50,000		8.42		0.25
	—		—		—		—		0.25		363,000		8.42		0.25
	—		—		—		—		0.28		25,000		2.42		0.28
	—		—		—		—		0.28		25,000		6.42		0.28
	—		—		—		—		0.29		25,000		4.20		0.29
	—		—		—		—		0.39		1,435,000		8.27		0.39
	—		—		—		—		0.59		1,400,000		4.13		0.59
	—		—		—		—		0.59		1,600,000		8.14		0.59
	—		—		—		—		0.92		350,000		3.76		0.92
	—		—		—		—		0.92		550,000		7.76		0.92
	—		—		—		—		1.33		25,000		0.07		1.33
	—		—		—		—		1.38		105,307		1.76		1.38
	—		—		—		—		1.67		405,943		1.51		1.67
	—		—		—		—		1.75		250,000		0.27		1.75
	—		—		—		—		1.78		25,000		1.43		1.78
	—		—		—		—		2.31		250,000		0.76		2.31
	—		—		—		—		4.15		25,000		1.26		4.15
	0.15-0.18		11,565,000				0.16		0.01-4.15		14,901,250				0.40

16

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

Granted to employees

The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date	$	0.06		$	0.15
Dividend yields		—			—
Expected volatility		137	%		127%-133	%
Risk-free interest rates		3.85	%		1.37%-1.55	%
Expected lives (in years)		5.00			5.00-5.50
Weighted-average grant date fair value	$	0.06		$	0.13

Granted to non-employees

The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date		—		$	0.15
Dividend yields		—			—
Expected volatility		—	%		103	%
Risk-free interest rates		—	%		1.78	%
Expected lives (in years)		—			10
Weighted-average grant date fair value		—		$	0.14

There were no warrants or options granted to non-employees for the 3 months ended March 31, 2023. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options.

The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life.

17

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

C. Compensation Cost for Warrant and Option Issuances 

The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	415		214

The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	2		1

The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	—		7

As of March 31, 2023, there was $434,000 of unrecognized compensation cost related to non-vested stock options granted under the Company’s various stock option plans. That cost is expected to be recognized during 2023.

18

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

D. Dividend Reinvestment and Stock Purchase Plan (“DSPP ”)

On March 13, 2014 Zion filed a registration statement on Form S-3 that was part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.

On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended.

On January 13, 2015, the Company amended the Original Prospectus Supplement (“Amendment No. 3”) to provide for a unit option (the “Unit Option”) under the DSPP comprised of one share of Common Stock and three Common Stock purchase warrants with each unit priced at $4.00. Each warrant afforded the participant the opportunity to purchase the Company’s Common Stock at a warrant exercise price of $1.00. Each of the three warrants series had different expiration dates that had been extended.

The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00.

As of May 2, 2017, any outstanding ZNWAB warrants expired.

As of May 2, 2018, any outstanding ZNWAC warrants expired.

On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.”

The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

19

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advanced notice to the warrant holders.

On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.”

All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.

An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017.

Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” 

The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2024 at a revised per share exercise price of $.25. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.

20

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.”

The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.”

The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.”

21

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01.

On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of February 25, 2023, any outstanding ZNWAK warrants expired.

On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering.

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.”

The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00.

On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2023 at a revised per share exercise price of $.05.

On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to $0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021.

22

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.”

The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00.

On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021.

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.”

The warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25.

On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. 

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and are exercisable through July 6, 2023 at a revised per share exercise price of $.05.

23

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program.

On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of $.25.

On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein.

On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on September 30, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAT.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on December 31, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAU.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25.

24

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a program consisting of shares of stock to a participant. After conclusion of the program on June 16, 2023, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock that will be acquired.

On March 13, 2023, Zion filed with the Securities and Exchange Commission an Amendment No. 2 to the Prospectus Supplement dated as of December 15, 2021 and accompanying base prospectus dated December 1, 2021 relating to the Company’s Dividend Reinvestment and Direct Stock Purchase Plan. This Amendment No. 2 to Prospectus Supplement amends the Prospectus Supplement. The Prospectus forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-261452), as amended, which was declared effective by the SEC on December 15, 2021.

Amendment No. 2 - New Unit Option under the Unit Program

Under our Plan, we provided a Unit Option under Amendment No. 2. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 2 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option had up to three tranches of investment, in which the second and third tranches were each subject to termination upon a total of $7,500,000 received from participants by the Company during the first or second tranche. The first tranche period began on March 13, 2023 and terminated on March 26, 2023. The second tranche began on March 27, 2023 and terminated on April 9, 2023 and the third tranche began on April 10, 2023 and terminated on April 27, 2023.

The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional five hundred (500) shares of Common Stock at a per share exercise price of $0.05. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.05. The warrant shall have the Company notation of “ZNWAV” under the first tranche, “ZNWAW” under the second tranche and “ZNWAX” under the third tranche. The warrants will not be registered for trading on the OTCQX or any other stock market or trading market.

Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month, received an additional fifty (50) warrants at an exercise price of $0.05 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program and shall have the Company notation of “ZNWAY.” Existing subscribers to the AMI are entitled to the additional fifty (50) warrants, if they purchase at least one (1) Unit during the Unit program. Plan participants, who enroll in the AMI at a minimum of $100 per month, will receive one hundred (100) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $250 per month, will receive two hundred and fifty (250) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $500 per month, will receive five hundred (500) ZNWAY warrants. The AMI program requires 90 days of participation to receive the ZNWAY warrants. Existing AMI participants are entitled to participate in this monthly program by increasing their monthly amount above the minimum $50.00 per month.

The ZNWAV warrants became exercisable on March 31, 2023 and continue to be exercisable through June 28, 2023 at a per share exercise price of $0.05. The ZNWAW warrants became exercisable on April 14, 2023 and continue to be exercisable through July 13, 2023 at a per share exercise price of $0.05. The ZNWAX warrants became exercisable on May 2, 2023 and continue to be exercisable through July 31, 2023 at a per share exercise price of $0.05. The ZNWAY warrants will become exercisable on June 12, 2023 and will continue to be exercisable through September 10, 2023 at a per share exercise price of $0.05.

For the three months ended March 31, 2023, and 2022, approximately $792,000 and $11,427,000 were raised under the DSPP program, respectively.

The company raised approximately $761,000 from the period April 1, 2023 through May 9, 2023, under the DSPP program.

The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.

25

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

E. Warrant Table 

The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below:

Warrants	Exercise Price		Warrant Termination Date	Outstanding Balance, 12/31/2022		Warrants Issued		Warrants Exercised			Warrants Expired			Outstanding Balance, 03/31/2023
ZNWAA	$	2.00	01/31/2024		1,498,804		-		-			-			1,498,804
ZNWAD	$	1.00	05/02/2023		243,853		-		-			-			243,853
ZNWAE	$	1.00	05/01/2023		2,144,099		-		-			-			2,144,099
ZNWAF	$	1.00	08/14/2023		359,435		-		-			-			359,435
ZNWAG	$	1.00	01/08/2024		240,068		-		-			-			240,068
ZNWAH	$	5.00	04/19/2023		372,400		-		-			-			372,400
ZNWAI	$	3.00	06/29/2023		640,710		-					-			640,710
ZNWAJ	$	1.00	10/29/2023		545,900		-		-			-			545,900
ZNWAK	$	0.01	02/25/2023		424,225		-		(9,050	)		(415,175	)		-
ZNWAL	$	2.00	08/26/2023		517,875		-		-			-			517,875
ZNWAM	$	0.05	07/15/2023		4,376,000		-		-			-			4,376,000
ZNWAN	$	1.00	05/16/2023		267,760		-		(50	)		-			267,710
ZNWAO	$	0.25	06/12/2023		174,660		-		-			-			174,660
ZNWAQ	$	0.05	07/06/2023		23,428,348		-		-			-			23,428,348
ZNWAV	$	0.05	06/28/2023		-		286,500		-			-			286,500
Outstanding warrants					35,234,137		286,500		(9,100	)		(415,175	)		35,096,362

26

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders’ Equity (cont’d)

F. Warrant Descriptions 

The price and the expiration dates for the series of warrants to investors are as follows *:

		Period of Grant	US$		Expiration Date
ZNWAA Warrants	B,C,G	March 2013 – December 2014		2.00	January 31, 2024
ZNWAD Warrants	H	January 2015 – March 2016		1.00	May 02, 2023
ZNWAE Warrants	H	November 2016 – March 2017		1.00	May 01, 2023
ZNWAF Warrants	A,B,C	May 2017 – July 2017		1.00	August 14, 2023
ZNWAG Warrants	C,G	October 2017 – December 2017		1.00	January 08, 2024
ZNWAH Warrants	H	February 2018		5.00	April 19, 2023
ZNWAI Warrants	A,B,C	April 2018 – May 2018		3.00	June 29, 2023
ZNWAJ Warrants	B,C	August 2018 – September 2018		1.00	October 29, 2023
ZNWAK Warrants	H	December 2018 – January 2019		0.01	February 25, 2023
ZNWAL Warrants	C	July 2019 – August 2019		2.00	August 26, 2023
ZNWAM Warrants	D,I	January 2021 – March 2021		0.05	July 15, 2023
ZNWAN Warrants		May – June 2021		1.00	May 16, 2023
ZNWAO Warrants		June 2021		0.25	June 12, 2023
ZNWAQ Warrants	E,I	June 2021		0.05	July 6, 2023
ZNWAS Warrants	F	August 2021 – March 2022		0.25	December 31, 2025
ZNWAT Warrants	F	August – September 2022		0.25	December 31, 2025
ZNWAU Warrants	F	October – November 2022		0.25	December 31, 2025
ZNWAV Warrants	J	March 2023		0.05	June 28, 2023
ZNWAW Warrants	J	March – April 2023		0.05	July 13, 2023
ZNWAX Warrants	J	April 2023		0.05	July 31, 2023
ZNWAY Warrants	K	March – April 2023		0.05	Sept 10, 2023

* Zion’s ZNWAB Warrants expired on May 2, 2017, the ZNWAC Warrants expired on May 2, 2018, the ZNWAD Warrants expired on May 2, 2023, the ZNWAE Warrants expired on May 1, 2023, the ZNWAH Warrants expired on April 19, 2023, and the ZNWAK Warrants expired on February 25, 2023.

A	On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.
B	On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.
C	On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.
D	On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year.
E	These warrants were issued on May 5, 2022, and on May 17, 2022, the Company extended the expiration date of the Warrants by one (1) year.
F	These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.
G	On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year.
H	These warrants are now expired as of the report date.
I	The warrant exercise price was lowered to $0.05 on December 28, 2022.
J	On March 13, 2023, The Company announced a new Unit Offering, inclusive of three tranches of warrants (ZNWAV, ZNWAW and ZNWAX).

K The ZNWAY warrants are associated with Automatic Monthly Investments (“AMI”) connected with participation in the unit offering announced on March 13, 2023

27

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 4 - Unproved Oil and Gas Properties, Full Cost Method

Unproved oil and gas properties, under the full cost method, are comprised as follows:

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		2,414		2,362
Capitalized salary costs		2,368		2,342
Capitalized interest costs		1,418		1,418
Legal and seismic costs, license fees and other preparation costs		9,818		9,728
Other costs		39		39
		16,057		15,889

Impairment of unproved oil and gas properties comprised as follows: 

	For the three months ended March 31,
	2023		2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		11		-
Capitalized salary costs		-		-
Capitalized interest costs		-		-
Legal and seismic costs, license fees and other preparation costs		34		-
		45		-

Changes in Unproved oil and gas properties during the three months ended March 31, 2023 and 2022 are as follows:

	March 31, 2023			March 31, 2022
	US$ thousands			US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		63			628
Capitalized salary costs		26			52
Capitalized interest costs		-			-
Legal and seismic costs, license fees and other preparation costs		124			469
Other costs		-			-
Impairment of unproved oil and gas properties		(45	)		-
		*168			*1,149

* Inclusive of non-cash amounts of approximately $1,515,000, and $1,137,000 during the three months ended March 31, 2023, and 2022, respectively

Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

28

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 5 - Right of use lease assets and lease obligations 

The Company is a lessee in several non-cancellable operating leases for transportation and office space.

The table below presents the operating lease assets and liabilities recognized on the balance sheets as of March 31, 2023 and December 31, 2022: 

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Operating lease assets	$	135	$	202
Operating lease liabilities:
Current operating lease liabilities	$	125	$	196
Non-current operating lease liabilities	$	12	$	12
Total operating lease liabilities	$	137	$	208

The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.

The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.

The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2023 are:

	March 31, 2023
Weighted average remaining lease term (years)		0.75
Weighted average discount rate		4.9	%

29

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 5 - Right of use lease assets and leases obligations (cont’d)

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of March 31, 2023:

	US$ thousands
2023		128
2024		11
2025		-
2026		-
Thereafter		-
Total undiscounted future minimum lease payments		139
Less: portion representing imputed interest		(2	)
Total undiscounted future minimum lease payments		137

Operating lease costs were $69,000 and $68,000 for the three months ended March 31, 2023, and 2022, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations.

Cash paid for amounts included in the measurement of operating lease liabilities was $70,000 and $72,000 for the three months ended March 31, 2023, and 2022, respectively, and this amount is included in operating activities in the statements of cash flows.

Right-of-use assets obtained in exchange for new operating lease liabilities were $nil and $nil for the three months ended March 31, 2023, and 2022, respectively.

30

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 6 - Commitments and Contingencies

A. Securities and Exchange Commission (“SEC”) Investigation 

As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.”

B. Litigation 

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. 

The Company is not subject to any litigation at the present time. 

C. Market Conditions – Coronavirus Pandemic 

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. While there are various uncertainties to navigate, the Company’s business activities are continuing. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. We cannot predict whether, when or the manner in which the conditions surrounding COVID-19 will change including the timing of lifting any restrictions or work from home arrangements.

The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others.

D. Environmental and Onshore Licensing Regulatory Matters 

The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings.

The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells.

As of March 31, 2023, and December 31, 2022, the Company accrued $nil and $nil for license regulatory matters.

E. Bank Guarantees 

As of March 31, 2023, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $1,042,000) and others (approximately $76,000) with respect to its drilling operation in an aggregate amount of approximately $1,118,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted.

31

Zion Oil & Gas, Inc.

Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 6 - Commitments and Contingencies (cont’d)

F. Risks 

Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.

Foreign Currency Exchange Rate Risks. A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels (“NIS”). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar (“USD”), our primary reporting currency. During the period January 1, 2023 through March 31, 2023, the USD has fluctuated by approximately 2.7% against the NIS (the USD strengthened relative to the NIS). Also, during the period January 1, 2022 through December 31, 2022, the USD fluctuated by approximately 13.2% against the NIS (the USD strengthened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.

Interest Rate Risk. Our exposure to market risk relates to our cash and investments. We maintain an investment portfolio of short-term bank deposits and money market funds. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment. At March 31, 2023, we had cash, cash equivalents and short-term bank deposits of approximately $2,159,000. The weighted average annual interest rate related to our cash and cash equivalents for the three months ended March 31, 2023, exclusive of funds at US banks that earn no interest, was approximately 2.61%.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

Note 7 - Subsequent Events

(i) Approximately $761,000 was collected through the Company’s DSPP program during the period April 1 through May 9, 2023.

32

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH OUR UNAUDITED INTERIM FINANCIAL STATEMENTS AND THE RELATED NOTES TO THOSE STATEMENTS INCLUDED IN THIS FORM 10-Q. SOME OF OUR DISCUSSION IS FORWARD-LOOKING AND INVOLVES RISKS AND UNCERTAINTIES. FOR INFORMATION REGARDING RISK FACTORS THAT COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, REFER TO THE DISCUSSION OF RISK FACTORS IN THE “DESCRIPTION OF BUSINESS” SECTION OF OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2022, FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Forward-Looking Statements

Certain statements made in this discussion are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may materially differ from actual results.

Forward-looking statements can be identified by terminology such as “may”, “should”, “expects”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, or “continue” or the negative of these terms or other comparable terminology and include, without limitation, statements regarding: 

● The going concern qualification in our consolidated financial statements;

● our ability to obtain new license areas to continue our petroleum exploration program;     ·

● our liquidity and our ability to raise capital to finance our overall exploration and development activities within our license area;

● our ability to continue meeting the requisite continued listing requirements by OTCQX;

● business interruptions from COVID-19 pandemic;

● interruptions, increased consolidated financial costs and other adverse impacts of the coronavirus pandemic on the drilling and testing of our petroleum exploration program and our capital raising efforts;

● our ability to explore for and develop natural gas and oil resources successfully and economically within a license area;

● our ability to maintain the exploration license rights to continue our petroleum exploration program;

● the availability of equipment, such as seismic equipment, drilling rigs, and production equipment as well as access to qualified personnel;

● the impact of governmental regulations, permitting and other legal requirements in Israel relating to onshore exploratory drilling;

● our estimates of the time frame within which future exploratory activities will be undertaken;

● changes in our exploration plans and related budgets;

33

● the quality of existing and future license areas with regard to, among other things, the existence of hydrocarbon reserves in economic quantities;

● anticipated trends in our business;

● our future results of operations;

● our capital expenditure program;

● future market conditions in the oil and gas industry

● the demand for oil and natural gas, both locally in Israel and globally; and

● the impact of fluctuating oil and gas prices on our exploration efforts

All references in this Quarterly Report to the “Company”, “Zion”, “we”, “us”, or “our”, are to Zion Oil and Gas, Inc., a Delaware corporation, and its wholly-owned subsidiaries, Zion Drilling, Inc. and Zion Drilling Services, Inc. described below.

Current Exploration and Operation Efforts

Zion Oil and Gas, Inc., a Delaware corporation, is an oil and gas exploration company with a history of 23 years of oil and gas exploration in Israel. We were incorporated in Florida on April 6, 2000 and reincorporated in Delaware on July 9, 2003. We completed our initial public offering in January 2007. Our common stock, par value $0.01 per share (the “Common Stock”) currently trades on the OTCQX marketplace of OTC Markets, Inc. under the symbol “ZNOG” and our Common Stock warrant under the symbol “ZNOGW.” On January 24, 2020, the Company incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, the Company incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When the Company is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect.

The New Megiddo License 428 (“NML 428”) was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

Prior to the filing of this Quarterly Report, we received initial administrative approval from various departments within the Israel Ministry of Energy which puts us in an excellent position to obtain final approval of our license.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

We are focusing on finalizing the technical and operational preparations for our re-entry of the MJ-01 well.

I-35 Drilling Rig & Associated Equipment

	Three-month period ended March 31, 2023
	I-35 Drilling Rig			Rig Spare Parts			Other Drilling Assets			Total
	US$ thousands			US$ thousands			US$ thousands			US$ thousands
December 31, 2022		5,225			619			437			6,281
Asset Additions		-			-			-			-
Asset Depreciation		(159	)		-			(32	)		(191	)
Asset Disposals for Self-Consumption		-			(10	)		-			(10	)
March 31, 2023		5,066			609			405			6,080

Zion’s ability to fully undertake all of these aforementioned activities is subject to its raising the needed capital from its continuing offerings, of which no assurance can be provided.

34

 

Map 1. Zion’s New Megiddo License 428 as of March 31, 2023.

35

Onshore Licensing, Oil and Gas Exploration and Environmental Guidelines

The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental cleanup of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner, the Energy Ministry, and the Environmental Ministry in recent years as it pertains to oil and gas activities. Mention of these guidelines was included in previous Zion Oil & Gas filings.

We acknowledge that these new regulations are likely to increase the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that additional financial burdens could occur as a result of the Ministry requiring cash reserves that could otherwise be used for operational purposes. 

Capital Resources Highlights

We need to raise significant funds to finance the continued exploration efforts and maintain orderly operations. To date, we have funded our operations through the issuance of our securities and convertible debt. We will need to continue to raise funds through the issuance of equity and/or debt securities (or securities convertible into or exchangeable for equity securities). No assurance can be provided that we will be successful in raising the needed capital on terms favorable to us (or at all).

The Dividend Reinvestment and Stock Purchase Plan

On March 13, 2014 Zion filed a registration statement on Form S-3 that is part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.

On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended.

Please see Footnote 3D (“Dividend Reinvestment and Stock Purchase Plan (“DSPP”)), which is a part of this Form 10-Q filing, for details about specific stock purchase and unit programs, dates, and filings during the years 2016 through 2023.

For the three months ended March 31, 2023, and 2022, approximately $792,000, and $11,427,000 were raised under the DSPP program, respectively.

The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below:

Warrants	Exercise Price		Warrant Termination Date	Outstanding Balance, 12/31/2022		Warrants Issued		Warrants Exercised			Warrants Expired			Outstanding Balance, 03/31/2023
ZNWAA	$	2.00	01/31/2024		1,498,804		-		-			-			1,498,804
ZNWAD	$	1.00	05/02/2023		243,853		-		-			-			243,853
ZNWAE	$	1.00	05/01/2023		2,144,099		-		-			-			2,144,099
ZNWAF	$	1.00	08/14/2023		359,435		-		-			-			359,435
ZNWAG	$	1.00	01/08/2024		240,068		-		-			-			240,068
ZNWAH	$	5.00	04/19/2023		372,400		-		-			-			372,400
ZNWAI	$	3.00	06/29/2023		640,710		-					-			640,710
ZNWAJ	$	1.00	10/29/2023		545,900		-		-			-			545,900
ZNWAK	$	0.01	02/25/2023		424,225		-		(9,050	)		(415,175	)		-
ZNWAL	$	2.00	08/26/2023		517,875		-		-			-			517,875
ZNWAM	$	0.05	07/15/2023		4,376,000		-		-			-			4,376,000
ZNWAN	$	1.00	05/16/2023		267,760		-		(50	)		-			267,710
ZNWAO	$	0.25	06/12/2023		174,660		-		-			-			174,660
ZNWAQ	$	0.05	07/06/2023		23,428,348		-		-			-			23,428,348
ZNWAV	$	0.05	06/28/2023		-		286,500		-			-			286,500
Outstanding warrants					35,234,137		286,500		(9,100	)		(415,175	)		35,096,362

36

Principal Components of our Cost Structure 

Our operating and other expenses primarily consist of the following:

● Impairment of Unproved Oil and Gas Properties: Impairment expense is recognized if a determination is made that a well will not be commercially productive. The amounts include amounts paid in respect of the drilling operations as well as geological and geophysical costs and various amounts that were paid to Israeli regulatory authorities.

● General and Administrative Expenses: Overhead, including payroll and benefits for our corporate staff, costs of managing our exploratory operations, audit and other professional fees, and legal compliance is included in general and administrative expenses. General and administrative expenses also include non-cash stock-based compensation expense, investor relations related expenses, lease and insurance and related expenses.

● Depreciation, Depletion, Amortization and Accretion: The systematic expensing of the capital costs incurred to explore for natural gas and oil represents a principal component of our cost structure. As a full cost company, we capitalize all costs associated with our exploration, and apportion these costs to each unit of production, if any, through depreciation, depletion and amortization expense. As we have yet to have production, the costs of abandoned wells are written off immediately versus being included in this amortization pool.

Going Concern Basis

Since we have limited capital resources, no revenue to date and a loss from operations, our consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. The appropriateness of using the going concern basis is dependent upon our ability to obtain additional financing or equity capital and, ultimately, to achieve profitable operations. Therefore, there is substantial doubt about our ability to continue as a going concern for one year from the date the financials were issued. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Impact of COVID-19 

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. As of the date of this report, the Company adopted a hybrid model whereby many of our employees are working from corporate office two to three days per week and then working remotely two to three days per week. While there are various uncertainties to navigate, the Company’s business activities are continuing.

The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others.

The main area in which Zion has experienced COVID-19’s impact has been in supply chain and/or logistics. We work with several suppliers worldwide for the procurement of oil and gas parts, inventory items and related labor for our ongoing operations for the MJ-02 well. Production delays, factory shutdowns and heavy demand by oil and gas operators worldwide for spare parts has created some challenges in obtaining these items in a timely fashion.

Critical Accounting Policies 

Management’s discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expense during the reporting period.

We have identified the accounting principles which we believe are most critical to the reported financial status by considering accounting policies that involve the most complex of subjective decisions or assessment.

37

Impairment of Oil and Gas Properties

We follow the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in income from continuing operations before income taxes, and the adjusted carrying amount of the unproved properties is amortized on the unit-of-production method.

Our oil and gas properties represent an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. A further impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

Abandonment of properties is accounted for as adjustments to capitalized costs. The net capitalized costs are subject to a “ceiling test” which limits such costs to the aggregate of the estimated present value of future net revenues from proved reserves discounted at ten percent based on current economic and operating conditions, plus the lower of cost or fair market value of unproved properties. The recoverability of amounts capitalized for oil and gas properties is dependent upon the identification of economically recoverable reserves, together with obtaining the necessary financing to exploit such reserves and the achievement of profitable operations.

During the three months ended March 31, 2023, and 2022, respectively, the Company recorded $45,000 and nil post-impairment charges.

The total net book value of our unproved oil and gas properties under the full cost method is $16,057,000 and $15,889,000 at March 31, 2023 and at December 31, 2022, respectively.

Asset Retirement Obligation

We record a liability for asset retirement obligation at fair value in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived assets.

Fair Value Considerations

We follow ASC 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

There are three levels of inputs to fair value measurements - Level 1, meaning the use of quoted prices for identical instruments in active markets; Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and Level 3, meaning the use of unobservable inputs. We use Level 1 inputs for fair value measurements whenever there is an active market, with actual quotes, market prices, and observable inputs on the measurement date. We use Level 2 inputs for fair value measurements whenever there are quoted prices for similar securities in an active market or quoted prices for identical securities in an inactive market. We use observable market data whenever available.

38

RESULTS OF OPERATIONS  

	For the three months ended March 31,
	2023		2022
	(US $ in thousands)
Operating costs and expenses:
General and administrative expenses		1,503		1,435
Other		583		711
Impairment of unproved oil and gas properties		45		-
Subtotal Operating costs and expenses		2,131		2,146
Other expense, net		8		20
Net loss		2,139		2,166

Revenue. We currently have no revenue generating operations.

Operating costs and expenses. Operating costs and expenses for the three months ended March 31, 2023 were $2,131,000 compared to $2,146,000 for the three months ended March 31, 2022.

General and administrative expenses. General and administrative expenses for the three months ended March 31, 2023 were $1,503,000, compared to $1,435,000 for the three months ended March 31, 2022. The increase in General and administrative expenses during the three months ended March 31, 2023 is primarily attributable to higher non-cash expenses recorded in connection with stock option grants.

Other expense. Other expense during the three months ended March 31, 2023 was $583,000 compared to $711,000 for the three months ended March 31, 2022. Other general and administrative expenses are comprised of non-compensation and non-professional expenses incurred. The decrease in other expenses is primarily attributable to lower marketing expenses associated with investor relations activities.

Impairment of unproved oil and gas properties. Impairment of unproved oil and gas properties expenses during the three months ended March 31, 2023 was $45,000 compared to nil for the three months ended March 31, 2022. The expenses recorded in 2023 are post impairment charges to the impairment recorded during 2022 related to the MJ-2 well.

Other expense, net. Other expense, net for the three months ended March 31, 2023 was $8,000, compared to $20,000 for the three months ended March 31, 2022.

Net Loss. Net loss for the three months ended March 31, 2023 was $2,139,000 compared to $2,166,000 for the three months ended March 31, 2022. The $27,000 lower net loss in 2023 is an immaterial difference compared to 2022.

39

Liquidity and Capital Resources

Liquidity is a measure of a company’s ability to meet potential cash requirements. As discussed above, we have historically met our capital requirements through the issuance of common stock as well as proceeds from the exercise of warrants and options to purchase common shares.

Our ability to continue as a going concern is dependent upon obtaining the necessary financing to complete further exploration and development activities and generate profitable operations from our oil and natural gas interests in the future. Our current operations are dependent upon the adequacy of our current assets to meet our current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, our ability to continue as a going concern will be impaired. Our financial statements for the three months ended March 31, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We have incurred a history of operating losses and negative cash flows from operations. Therefore, there is substantial doubt about our ability to continue as a going concern for one year from the date the financials were issued.

At March 31, 2023, we had approximately $799,000 in cash and cash equivalents compared to $1,735,000 at December 31, 2022, which does not include any restricted funds. Our working capital (current assets minus current liabilities) was ($148,000) at March 31, 2023 and $661,000 at December 31, 2022.

As of March 31, 2023, we provided bank guarantees to various governmental bodies (approximately $1,042,000) and others (approximately $76,000) in respect of our drilling operation in the aggregate amount of approximately $1,118,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company’s balance sheets as fixed short-term bank deposits restricted.

During the three months ended March 31, 2023, and 2022, cash used in operating activities totaled $917,000, and $2,091,000, respectively. Cash provided by financing activities during the three months ended March 31, 2023, and 2022, was $800,000, and $9,428,000, respectively, and is primarily attributable to proceeds received from the Dividend Reinvestment and Stock Purchase Plan (the “DSPP” or “Plan”). Net cash used in investing activities such as unproved oil and gas properties, equipment and spare parts was $838,000 and $3,799,000 for the three months ended March 31, 2023, and 2022, respectively.

Accounting standards require management to evaluate our ability to continue as a going concern for a period of one year subsequent to the date of the filing of this Form 10-Q. We expect to incur additional significant expenditures to further our exploration and development programs. While we raised approximately $761,000 during  the period April 1, 2023 through May 9, 2023, we will need to raise additional funds in order to continue our exploration and development activities in our license area. Additionally, we estimate that, when we are not actively drilling a well, our expenditures are approximately $600,000 per month excluding exploratory operational activities. However, when we are actively drilling a well, we estimate an additional minimum expenditure of approximately $2,500,000 per month. The above estimates are subject to change. Subject to the qualifications specified below, management believes that our existing cash balance, coupled with anticipated proceeds under the DSPP, will be sufficient to finance our plan of operations through May 2023.

The outbreak of the coronavirus has to date significantly disrupted business operations and resulted in significantly increased unemployment in the general economy. The extent to which the coronavirus impacts our operations, specifically our capital raising efforts, as well as our ability to continue our exploratory efforts, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.

No assurance can be provided that we will be able to raise the needed operating capital.

Even if we raise the needed funds, there are factors that can nevertheless adversely impact our ability to fund our operating needs, including (without limitation), unexpected or unforeseen cost overruns in planned non-drilling exploratory work in existing license areas, the costs associated with extended delays in undertaking the required exploratory work, and plugging and abandonment activities which is typical of what we have experienced in the past. 

The financial information contained in these consolidated financial statements has been prepared on a basis that assumes that we will continue as a going concern for one year from the date the financials were issued, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. This financial information and these consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty. 

40

Off-Balance Sheet Arrangements

We do not currently use any off-balance sheet arrangements to enhance our liquidity or capital resource position, or for any other purpose.

Recently Issued Accounting Pronouncements

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our financial position, results of operations, or cash flow.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.

Foreign Currency Exchange Rate Risks. A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels (“NIS”). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar (“USD”), our primary reporting currency. During the period January 1, 2023 through March 31, 2023, the USD has fluctuated by approximately 2.7% against the NIS (the USD strengthened relative to the NIS). Also, during the period January 1, 2022 through December 31, 2022, the USD fluctuated by approximately 13.2% against the NIS (the USD strengthened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.

Interest Rate Risk. Our exposure to market risk relates to our cash and investments. We maintain an investment portfolio of short-term bank deposits and money market funds. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment. At March 31, 2023 we had cash, cash equivalents and short-term and long-term bank deposits of approximately $2,159,000. The weighted average annual interest rate related to our cash and cash equivalents for the three months ended March 31, 2023, exclusive of funds at US banks that earn no interest, was approximately 2.61%.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

ITEM 4. CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms. As of March 31, 2023, our chief executive officer and our chief financial officer conducted an evaluation of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2023.

Changes in Internal Control over Financial Reporting

There were no changes in internal controls over financial reporting that occurred during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

41

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Securities and Exchange Commission (“SEC”) Investigation

As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.”

Litigation

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. 

The Company is not subject to any litigation at the present time. 

ITEM 1A. RISK FACTORS

During the quarter ended March 31, 2023, there were no material changes to the risk factors previously reported in our Annual Report on Form 10-K for the year ended December 31, 2022. 

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION:

None.

ITEM 6. EXHIBITS

42

Exhibit Index:

31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 under the Exchange Act
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 under the Exchange Act
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished only)
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished only)
101.INS	XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

43

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ZION OIL & GAS, INC.
(Registrant)
By:	/s/ Robert W.A. Dunn	By:	/s/ Michael B. Croswell Jr.
	Robert W. A. Dunn		Michael B. Croswell Jr.
	Chief Executive Officer		Chief Financial Officer
	(Principal Executive Officer)		(Principal Financial and Accounting Officer)
Date:	May 11, 2023	Date:	May 11, 2023

44

EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

I, Robert W. A. Dunn, certify that:

1. I have reviewed this annual report on Form 10-Q of Zion Oil & Gas, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

/s/ Robert W. A. Dunn 

Robert W. A. Dunn, Chief Executive Officer

(Principal Executive Officer)

EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)

I, Michael B. Croswell Jr, certify that:

1. I have reviewed this annual report on Form 10-Q of Zion Oil & Gas, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

/s/ Michael B. Croswell Jr.

Michael B. Croswell Jr, Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Zion Oil and Gas, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2023 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, I, Robert W.A. Dunn, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented in the Report.

/s/ Robert W. A. Dunn

Robert W. A. Dunn

Chief Executive Officer

(Principal Executive Officer)

May 11, 2023

EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Zion Oil and Gas, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2023 (the "Report"), as filed with the Securities and Exchange Commission on the date hereof, I, Michael B. Croswell Jr., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods presented in the Report.

/s/ Michael B. Croswell Jr.

Michael B. Croswell Jr.

Chief Financial Officer

(Principal Financial and Accounting Officer)

May 11, 2023

XML

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Document Information Line Items
Entity Registrant Name	ZION OIL & GAS INC
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		540,313,673
Amendment Flag	false
Entity Central Index Key	0001131312
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0065053
Entity Address, Address Line One	12655 N Central Expressway
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
City Area Code	(214)
Local Phone Number	221-4610
Title of 12(b) Security	N/A
Security Exchange Name	NONE
Entity Interactive Data Current	Yes
Entity File Number	001-33228

XML

Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Cash and cash equivalents	$ 799	$ 1,735
Fixed short term bank and escrow deposits – restricted	1,360	1,379
Prepaid expenses and other current assets	581	600
Other deposits	155	483
Governmental receivables	26	267
Other receivables	139	143
Total current assets	3,060	4,607
Unproved oil and gas properties, full cost method (see Note 4)	16,057	15,889
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $1,645 and $1,455 (see note 2I)	6,080	6,281
Property and equipment, net of accumulated depreciation of $657 and $647	102	112
Property Plant and Equipment Net	6,182	6,393
Right of Use Lease Assets (see Note 5)	135	202
Other assets
Assets held for severance benefits	425	424
Total other assets	425	424
Total assets	25,859	27,515
Current liabilities
Accounts payable	2,017	2,147
Lease obligation – current (see Note 5)	125	196
Asset retirement obligation	571	571
Accrued liabilities	495	1,032
Total current liabilities	3,208	3,946
Long-term liabilities
Lease obligation – non-current (see Note 5)	12	12
Provision for severance pay	461	457
Total long-term liabilities	473	469
Total liabilities	3,681	4,415
Commitments and contingencies (see Note 6)
Common stock, par value $.01; Authorized: 800,000,000 shares at March 31, 2023: Issued and outstanding: 533,713,261 and 524,231,493 shares at March 31, 2023 and December 31, 2022, respectively	5,337	5,242
Additional paid-in capital	297,582	296,460
Accumulated deficit	(280,741)	(278,602)
Total stockholders’ equity	22,178	23,100
Total liabilities and stockholders’ equity	$ 25,859	$ 27,515

XML

Consolidated Condensed Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Drilling rig and related equipment, net of accumulated depreciation (in Dollars)	$ 1,645	$ 1,455
Accumulated depreciation (in Dollars)	$ 657	$ 647
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	800,000,000	800,000,000
Common stock, issued	533,713,261	524,231,493
Common stock, outstanding	533,713,261	524,231,493

XML

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
General and administrative	$ 1,503	$ 1,435
Other	583	711
Post impairment of unproved oil and gas properties	45
Loss from operations	(2,131)	(2,146)
Other expense, net
Foreign exchange (loss)	(2)	(9)
Financial (expenses), net	(6)	(11)
Loss, before income taxes	(2,139)	(2,166)
Income taxes
Net loss	$ (2,139)	$ (2,166)
Net loss, per share of common stock
Basic and diluted (in Dollars per share)	$ (4.000)	$ (5.000)
Weighted-average shares outstanding
Basic and diluted (in Shares)	531,023,000	404,817,000

XML

Consolidated Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Diluted	$ (4)	$ (5)
Diluted	531,023,000	404,817,000

XML

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional paid-in Capital	Accumulated deficit	Total
Balance at Dec. 31, 2021	$ 3,643	$ 277,258	$ (223,525)	$ 57,376
Balance (in Shares) at Dec. 31, 2021	364,324
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,022	10,405		11,427
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	102,219
Funds received from option exercises	$ 1			1
Funds received from option exercises (in Shares)	50
Value of options granted to employees, directors and others as non-cash compensation		215		215
Net loss			(2,166)	(2,166)
Balance at Mar. 31, 2022	$ 4,666	287,878	(225,691)	66,853
Balance (in Shares) at Mar. 31, 2022	466,593
Balance at Dec. 31, 2022	$ 5,242	296,460	(278,602)	23,100
Balance (in Shares) at Dec. 31, 2022	524,231
Funds received from sale of DSPP units and shares and exercise of warrants	$ 94	698		792
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	9,357
Funds received from option exercises	$ 1	7		8
Funds received from option exercises (in Shares)	125
Value of options granted to employees, directors and others as non-cash compensation		417		417
Net loss			(2,139)	(2,139)
Balance at Mar. 31, 2023	$ 5,337	$ 297,582	$ (280,741)	$ 22,178
Balance (in Shares) at Mar. 31, 2023	533,713

XML

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (2,139)	$ (2,166)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	200	195
Cost of options issued to employees, directors and others as non-cash compensation	417	208
Post impairment of unproved oil and gas properties	45
Change in assets and liabilities, net:
Other deposits	328	12
Prepaid expenses and other	19	(575)
Governmental receivables	241	562
Lease obligation – current	(71)	(34)
Lease obligation – non current		(40)
Right of use lease assets	67	64
Other receivables	4	107
Severance payable, net	3
Accounts payable	26	(331)
Accrued liabilities	(57)	(93)
Net cash used in operating activities	(917)	(2,091)
Cash flows from investing activities
Acquisition of property and equipment		(12)
Acquisition of drilling rig and related equipment		(122)
Investment in unproved oil and gas properties	(838)	(3,665)
Net cash used in investing activities	(838)	(3,799)
Cash flows from financing activities
Proceeds from exercise of stock options	8	1
Proceeds from issuance of stock and exercise of warrants	792	9,427
Net cash provided by financing activities	800	9,428
Net (decrease)/increase in cash, cash equivalents and restricted cash	(955)	3,538
Cash, cash equivalents and restricted cash – beginning of period	3,114	5,952
Cash, cash equivalents and restricted cash – end of period	2,159	9,490
Non-cash investing and financing activities:
Non-cash equity receivables		2,000
Unpaid investments in oil & gas properties	1,515	1,130
Capitalized convertible bond interest attributed to oil and gas properties
Cost of options issued to employees attributed to oil and gas properties		$ 7

XML

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Cash and cash equivalents	$ 799	$ 1,735
Restricted cash included in fixed long-term bank deposits	1,360	1,379
Total	$ 2,159	$ 3,114

XML

Nature of Operations, Basis of Presentation and Going Concern

3 Months Ended

Mar. 31, 2023

Nature of Operations, Basis of Presentation and Going Concern [Abstract]

Nature of Operations, Basis of Presentation and Going Concern

Note 1 - Nature of Operations, Basis of Presentation and Going Concern

A. Nature of Operations 

Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 23 years of oil & gas exploration in Israel. As of March 31, 2023, the Company has no revenues from its oil and gas operations.

Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company.

On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect.

Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel.

Exploration Rights/Exploration Activities

New Megiddo License 428 (“NML 428”)

The New Megiddo License 428 (“NML 428”) was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

Prior to the filing of this Quarterly Report, we received initial administrative approval from various departments within the Israel Ministry of Energy which puts us in an excellent position to obtain final approval of our license.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

We are focusing on finalizing the technical and operational preparations for our re-entry of the MJ-01 well.

B. Basis of Presentation 

The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the year ending December 31, 2023 or for any other subsequent interim period.

C. Going Concern 

The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. 

The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the three months ended March 31, 2023, the Company incurred a net loss of approximately $2.2 million and had an accumulated deficit of approximately $281 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the financials were issued.

To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty 

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

A. Net Loss per Share Data 

Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share as the inclusion of 57,997,687 and 23,144,603 Common Stock equivalents in 2023, and 2022 respectively, would be anti-dilutive.

B. Use of Estimates 

The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

C. Oil and Gas Properties and Impairment 

The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method.

The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $45,615,000.

During the three months ended March 31, 2023, the Company recorded post-impairment charges of $45,000. During the three months ended March 31, 2022, the Company did not record any post-impairment charges.

Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $16,057,000 and $15,889,000 as of March 31, 2023 and December 31, 2022, respectively.

D. Fair Value Measurements 

The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At March 31, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.  

E. Stock-Based Compensation 

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

F. Warrants 

In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity.

G. Related parties 

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged.

Zion did not have any related party transactions for the periods covered in this report.

H. Recently Adopted Accounting Pronouncements 

In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

 In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. Zion adopted ASU 2021-08 in the first quarter of 2023. The adoption of this ASU did not have a material impact on our consolidated financial statements; the impact in future periods will be dependent upon the contract assets acquired and contract liabilities assumed in any future business combinations.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a roll forward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for roll forward information, which is effective for fiscal years beginning after December 15, 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

Other Recent Accounting Pronouncements

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow.

I. Depreciation and Accounting for Drilling Rig and Related Equipment 

On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021.

The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet.

In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion will depreciate the rig on a straight-line basis.

Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed.

It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly.

See the table below for a reconciliation of the rig-related activity during the quarter ended March 31, 2023:

I-35 Drilling Rig & Associated Equipment:

	Three-month period ended March 31, 2023
	I-35 Drilling Rig			Rig Spare Parts			Other Drilling Assets			Total
	US$ thousands			US$ thousands			US$ thousands			US$ thousands
December 31, 2022		5,225			619			437			6,281
Asset Additions		-			-			-			-
Asset Depreciation		(159	)		-			(32	)		(191	)
Asset Disposals for Self-Consumption		-			(10	)		-			(10	)
March 31, 2023		5,066			609			405			6,080

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 3 - Stockholders’ Equity

The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 400,000,000 shares to 800,000,000 shares, effective June 9, 2021.

A. 2021 Omnibus Incentive Stock Option Plan

Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock.

The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions.

The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant.

During the three months ended March 31, 2023, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

i. Options to purchase 175,000 shares of Common Stock to five senior officers and one staff member at an exercise price of $0.0615 per share. The options vested upon grant and are exercisable through January 4, 2033. The fair value of the options at the date of grant amounted to approximately $9,000.

ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $1,500.

During the three months ended March 31, 2022, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

i. Options to purchase 175,000 shares of Common Stock to six senior officers and one staff member at an exercise price of $0.1529 per share. The options vested upon grant and are exercisable through January 4, 2032. The fair value of the options at the date of grant amounted to approximately $22,000.

ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $4,000.

iii. Options to purchase 300,000 shares of Common Stock to one senior officer and one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $39,000. 

iv. Options to purchase 200,000 shares of Common Stock one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $29,000. 

v. Options to purchase 1,600,000 shares of Common Stock to five senior officers and four staff members at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $209,000, and will be recognized during the years 2022 and 2023.

vi.	Options to purchase 1,400,000 shares of Common Stock to seven board members, at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $182,000, and will be recognized during the years 2022 and 2023.
vii.	Options to purchase 160,000 shares of Common Stock to four staff members, at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 17, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $23,000.
viii.	Options to purchase 200,000 shares of Common Stock to six staff members at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $26,000, and will be recognized during the years 2022 and 2023.
ix.	Options to purchase 40,000 shares of Common Stock to two consultants at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $5,000, and will be recognized during the years 2022 and 2023.

B. Stock Options 

The stock option transactions since January 1, 2023 are shown in the table below:

	Number of shares			Weighted Average exercise price
				US$
Outstanding, December 31, 2022		26,391,250			0.30
Changes during 2023 to:
Granted to employees, officers, directors and others		200,000			0.06
Expired/Cancelled/Forfeited		-			-
Exercised		(125,000	)		0.06
Outstanding, March 31, 2023		26,466,250			0.30
Exercisable, March 31, 2023		14,901,250			0.40

The following table summarizes information about stock options outstanding as of March 31, 2023:

Shares underlying outstanding options (non-vested)								Shares underlying outstanding options (fully vested)
Range of exercise price		Number outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price		Range of exercise price		Number Outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price
US$						US$		US$						US$
	0.15		6,410,000		9.05		0.15		0.01		10,000		0.62		0.01
	0.18		5,155,000		9.49		0.18		0.01		5,000		1.20		0.01
	—		—		—		—		0.01		20,000		3.17		0.01
	—		—		—		—		0.01		130,000		3.75		0.01
	—		—		—		—		0.01		50,000		3.76		0.01
	—		—		—		—		0.01		60,000		4.04		0.01
	—		—		—		—		0.01		200,000		4.13		0.01
	—		—		—		—		0.01		40,000		4.50		0.01
	—		—		—		—		0.01		70,000		4.75		0.01
	—		—		—		—		0.01		25,000		4.76		0.01
	—		—		—		—		0.01		30,000		4.91		0.01
	—		—		—		—		0.01		4,000		5.01		0.01
	—		—		—		—		0.01		25,000		5.77		0.01
	—		—		—		—		0.01		35,000		6.46		0.01
	—		—		—		—		0.01		150,000		6.63		0.01
	—		—		—		—		0.01		35,000		6.76		0.01
	—		—		—		—		0.01		75,000		7.76		0.01
	—		—		—		—		0.01		200,000		8.14		0.01
	—		—		—		—		0.01		300,000		8.29		0.01
	—		—		—		—		0.01		10,000		8.42		0.01
	—		—		—		—		0.01		500,000		8.76		0.01
	—		—		—		—		0.01		55,000		8.80		0.01
	—		—		—		—		0.01		960,000		9.04		0.01
	—		—		—		—		0.01		75,000		9.37		0.01
	—		—		—		—		0.01		10,000		9.42		0.01
	—		—		—		—		0.01		795,000		9.48		0.01
	—		—		—		—		0.01		25,000		9.76		0.01
	—		—		—		—		0.06		50,000		9.76		0.06
	—		—		—		—		0.14		240,000		8.80		0.14
	—		—		—		—		0.15		25,000		8.76		0.15
	—		—		—		—		0.15		3,200,000		9.00		0.15
	—		—		—		—		0.16		340,000		2.69		0.16
	—		—		—		—		0.16		75,000		6.69		0.16
	—		—		—		—		0.18		25,000		2.67		0.18
	—		—		—		—		0.24		25,000		9.34		0.24
	—		—		—		—		0.24		118,000		9.37		0.24
	—		—		—		—		0.25		50,000		8.42		0.25
	—		—		—		—		0.25		363,000		8.42		0.25
	—		—		—		—		0.28		25,000		2.42		0.28
	—		—		—		—		0.28		25,000		6.42		0.28
	—		—		—		—		0.29		25,000		4.20		0.29
	—		—		—		—		0.39		1,435,000		8.27		0.39
	—		—		—		—		0.59		1,400,000		4.13		0.59
	—		—		—		—		0.59		1,600,000		8.14		0.59
	—		—		—		—		0.92		350,000		3.76		0.92
	—		—		—		—		0.92		550,000		7.76		0.92
	—		—		—		—		1.33		25,000		0.07		1.33
	—		—		—		—		1.38		105,307		1.76		1.38
	—		—		—		—		1.67		405,943		1.51		1.67
	—		—		—		—		1.75		250,000		0.27		1.75
	—		—		—		—		1.78		25,000		1.43		1.78
	—		—		—		—		2.31		250,000		0.76		2.31
	—		—		—		—		4.15		25,000		1.26		4.15
	0.15-0.18		11,565,000				0.16		0.01-4.15		14,901,250				0.40

Granted to employees

The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date	$	0.06		$	0.15
Dividend yields		—			—
Expected volatility		137	%		127%-133	%
Risk-free interest rates		3.85	%		1.37%-1.55	%
Expected lives (in years)		5.00			5.00-5.50
Weighted-average grant date fair value	$	0.06		$	0.13

Granted to non-employees

The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date		—		$	0.15
Dividend yields		—			—
Expected volatility		—	%		103	%
Risk-free interest rates		—	%		1.78	%
Expected lives (in years)		—			10
Weighted-average grant date fair value		—		$	0.14

There were no warrants or options granted to non-employees for the 3 months ended March 31, 2023. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options.

The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life.

C. Compensation Cost for Warrant and Option Issuances 

The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	415		214

The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	2		1

The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties:

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	—		7

As of March 31, 2023, there was $434,000 of unrecognized compensation cost related to non-vested stock options granted under the Company’s various stock option plans. That cost is expected to be recognized during 2023.

D. Dividend Reinvestment and Stock Purchase Plan (“DSPP ”)

On March 13, 2014 Zion filed a registration statement on Form S-3 that was part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.

On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended.

On January 13, 2015, the Company amended the Original Prospectus Supplement (“Amendment No. 3”) to provide for a unit option (the “Unit Option”) under the DSPP comprised of one share of Common Stock and three Common Stock purchase warrants with each unit priced at $4.00. Each warrant afforded the participant the opportunity to purchase the Company’s Common Stock at a warrant exercise price of $1.00. Each of the three warrants series had different expiration dates that had been extended.

The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00.

As of May 2, 2017, any outstanding ZNWAB warrants expired.

As of May 2, 2018, any outstanding ZNWAC warrants expired.

On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.”

The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advanced notice to the warrant holders.

On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.”

All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.

An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017.

Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” 

The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2024 at a revised per share exercise price of $.25. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.

On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.”

The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.”

The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.”

The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01.

On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of February 25, 2023, any outstanding ZNWAK warrants expired.

On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering.

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.”

The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00.

On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2023 at a revised per share exercise price of $.05.

On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to $0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021.

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.”

The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00.

On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021.

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.”

The warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25.

On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. 

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and are exercisable through July 6, 2023 at a revised per share exercise price of $.05.

Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program.

On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of $.25.

On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein.

On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on September 30, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAT.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on December 31, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAU.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a program consisting of shares of stock to a participant. After conclusion of the program on June 16, 2023, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock that will be acquired.

On March 13, 2023, Zion filed with the Securities and Exchange Commission an Amendment No. 2 to the Prospectus Supplement dated as of December 15, 2021 and accompanying base prospectus dated December 1, 2021 relating to the Company’s Dividend Reinvestment and Direct Stock Purchase Plan. This Amendment No. 2 to Prospectus Supplement amends the Prospectus Supplement. The Prospectus forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-261452), as amended, which was declared effective by the SEC on December 15, 2021.

Amendment No. 2 - New Unit Option under the Unit Program

Under our Plan, we provided a Unit Option under Amendment No. 2. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 2 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option had up to three tranches of investment, in which the second and third tranches were each subject to termination upon a total of $7,500,000 received from participants by the Company during the first or second tranche. The first tranche period began on March 13, 2023 and terminated on March 26, 2023. The second tranche began on March 27, 2023 and terminated on April 9, 2023 and the third tranche began on April 10, 2023 and terminated on April 27, 2023.

The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional five hundred (500) shares of Common Stock at a per share exercise price of $0.05. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.05. The warrant shall have the Company notation of “ZNWAV” under the first tranche, “ZNWAW” under the second tranche and “ZNWAX” under the third tranche. The warrants will not be registered for trading on the OTCQX or any other stock market or trading market.

Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month, received an additional fifty (50) warrants at an exercise price of $0.05 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program and shall have the Company notation of “ZNWAY.” Existing subscribers to the AMI are entitled to the additional fifty (50) warrants, if they purchase at least one (1) Unit during the Unit program. Plan participants, who enroll in the AMI at a minimum of $100 per month, will receive one hundred (100) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $250 per month, will receive two hundred and fifty (250) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $500 per month, will receive five hundred (500) ZNWAY warrants. The AMI program requires 90 days of participation to receive the ZNWAY warrants. Existing AMI participants are entitled to participate in this monthly program by increasing their monthly amount above the minimum $50.00 per month.

The ZNWAV warrants became exercisable on March 31, 2023 and continue to be exercisable through June 28, 2023 at a per share exercise price of $0.05. The ZNWAW warrants became exercisable on April 14, 2023 and continue to be exercisable through July 13, 2023 at a per share exercise price of $0.05. The ZNWAX warrants became exercisable on May 2, 2023 and continue to be exercisable through July 31, 2023 at a per share exercise price of $0.05. The ZNWAY warrants will become exercisable on June 12, 2023 and will continue to be exercisable through September 10, 2023 at a per share exercise price of $0.05.

For the three months ended March 31, 2023, and 2022, approximately $792,000 and $11,427,000 were raised under the DSPP program, respectively.

The company raised approximately $761,000 from the period April 1, 2023 through May 9, 2023, under the DSPP program.

The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.

E. Warrant Table 

The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below:

Warrants	Exercise Price		Warrant Termination Date	Outstanding Balance, 12/31/2022		Warrants Issued		Warrants Exercised			Warrants Expired			Outstanding Balance, 03/31/2023
ZNWAA	$	2.00	01/31/2024		1,498,804		-		-			-			1,498,804
ZNWAD	$	1.00	05/02/2023		243,853		-		-			-			243,853
ZNWAE	$	1.00	05/01/2023		2,144,099		-		-			-			2,144,099
ZNWAF	$	1.00	08/14/2023		359,435		-		-			-			359,435
ZNWAG	$	1.00	01/08/2024		240,068		-		-			-			240,068
ZNWAH	$	5.00	04/19/2023		372,400		-		-			-			372,400
ZNWAI	$	3.00	06/29/2023		640,710		-					-			640,710
ZNWAJ	$	1.00	10/29/2023		545,900		-		-			-			545,900
ZNWAK	$	0.01	02/25/2023		424,225		-		(9,050	)		(415,175	)		-
ZNWAL	$	2.00	08/26/2023		517,875		-		-			-			517,875
ZNWAM	$	0.05	07/15/2023		4,376,000		-		-			-			4,376,000
ZNWAN	$	1.00	05/16/2023		267,760		-		(50	)		-			267,710
ZNWAO	$	0.25	06/12/2023		174,660		-		-			-			174,660
ZNWAQ	$	0.05	07/06/2023		23,428,348		-		-			-			23,428,348
ZNWAV	$	0.05	06/28/2023		-		286,500		-			-			286,500
Outstanding warrants					35,234,137		286,500		(9,100	)		(415,175	)		35,096,362

F. Warrant Descriptions 

The price and the expiration dates for the series of warrants to investors are as follows *:

		Period of Grant	US$		Expiration Date
ZNWAA Warrants	B,C,G	March 2013 – December 2014		2.00	January 31, 2024
ZNWAD Warrants	H	January 2015 – March 2016		1.00	May 02, 2023
ZNWAE Warrants	H	November 2016 – March 2017		1.00	May 01, 2023
ZNWAF Warrants	A,B,C	May 2017 – July 2017		1.00	August 14, 2023
ZNWAG Warrants	C,G	October 2017 – December 2017		1.00	January 08, 2024
ZNWAH Warrants	H	February 2018		5.00	April 19, 2023
ZNWAI Warrants	A,B,C	April 2018 – May 2018		3.00	June 29, 2023
ZNWAJ Warrants	B,C	August 2018 – September 2018		1.00	October 29, 2023
ZNWAK Warrants	H	December 2018 – January 2019		0.01	February 25, 2023
ZNWAL Warrants	C	July 2019 – August 2019		2.00	August 26, 2023
ZNWAM Warrants	D,I	January 2021 – March 2021		0.05	July 15, 2023
ZNWAN Warrants		May – June 2021		1.00	May 16, 2023
ZNWAO Warrants		June 2021		0.25	June 12, 2023
ZNWAQ Warrants	E,I	June 2021		0.05	July 6, 2023
ZNWAS Warrants	F	August 2021 – March 2022		0.25	December 31, 2025
ZNWAT Warrants	F	August – September 2022		0.25	December 31, 2025
ZNWAU Warrants	F	October – November 2022		0.25	December 31, 2025
ZNWAV Warrants	J	March 2023		0.05	June 28, 2023
ZNWAW Warrants	J	March – April 2023		0.05	July 13, 2023
ZNWAX Warrants	J	April 2023		0.05	July 31, 2023
ZNWAY Warrants	K	March – April 2023		0.05	Sept 10, 2023

* Zion’s ZNWAB Warrants expired on May 2, 2017, the ZNWAC Warrants expired on May 2, 2018, the ZNWAD Warrants expired on May 2, 2023, the ZNWAE Warrants expired on May 1, 2023, the ZNWAH Warrants expired on April 19, 2023, and the ZNWAK Warrants expired on February 25, 2023.

A	On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.
B	On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.
C	On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.
D	On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year.
E	These warrants were issued on May 5, 2022, and on May 17, 2022, the Company extended the expiration date of the Warrants by one (1) year.
F	These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.
G	On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year.
H	These warrants are now expired as of the report date.
I	The warrant exercise price was lowered to $0.05 on December 28, 2022.
J	On March 13, 2023, The Company announced a new Unit Offering, inclusive of three tranches of warrants (ZNWAV, ZNWAW and ZNWAX).

K The ZNWAY warrants are associated with Automatic Monthly Investments (“AMI”) connected with participation in the unit offering announced on March 13, 2023

XML

Unproved Oil and Gas Properties, Full Cost Method

3 Months Ended

Mar. 31, 2023

Unproved Oil and Gas Properties, Full Cost Method [Abstract]

Unproved Oil and Gas Properties, Full Cost Method

Note 4 - Unproved Oil and Gas Properties, Full Cost Method

Unproved oil and gas properties, under the full cost method, are comprised as follows:

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		2,414		2,362
Capitalized salary costs		2,368		2,342
Capitalized interest costs		1,418		1,418
Legal and seismic costs, license fees and other preparation costs		9,818		9,728
Other costs		39		39
		16,057		15,889

Impairment of unproved oil and gas properties comprised as follows: 

	For the three months ended March 31,
	2023		2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		11		-
Capitalized salary costs		-		-
Capitalized interest costs		-		-
Legal and seismic costs, license fees and other preparation costs		34		-
		45		-

Changes in Unproved oil and gas properties during the three months ended March 31, 2023 and 2022 are as follows:

	March 31, 2023			March 31, 2022
	US$ thousands			US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		63			628
Capitalized salary costs		26			52
Capitalized interest costs		-			-
Legal and seismic costs, license fees and other preparation costs		124			469
Other costs		-			-
Impairment of unproved oil and gas properties		(45	)		-
		*168			*1,149

* Inclusive of non-cash amounts of approximately $1,515,000, and $1,137,000 during the three months ended March 31, 2023, and 2022, respectively

Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

XML

Right of Use Lease Assets and Lease Obligations

3 Months Ended

Mar. 31, 2023

Right of Use Lease Assets and Lease Obligations [Abstract]

Right of use lease assets and lease obligations

Note 5 - Right of use lease assets and lease obligations 

The Company is a lessee in several non-cancellable operating leases for transportation and office space.

The table below presents the operating lease assets and liabilities recognized on the balance sheets as of March 31, 2023 and December 31, 2022: 

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Operating lease assets	$	135	$	202
Operating lease liabilities:
Current operating lease liabilities	$	125	$	196
Non-current operating lease liabilities	$	12	$	12
Total operating lease liabilities	$	137	$	208

The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.

The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.

The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of March 31, 2023 are:

	March 31, 2023
Weighted average remaining lease term (years)		0.75
Weighted average discount rate		4.9	%

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of March 31, 2023:

	US$ thousands
2023		128
2024		11
2025		-
2026		-
Thereafter		-
Total undiscounted future minimum lease payments		139
Less: portion representing imputed interest		(2	)
Total undiscounted future minimum lease payments		137

Operating lease costs were $69,000 and $68,000 for the three months ended March 31, 2023, and 2022, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations.

Cash paid for amounts included in the measurement of operating lease liabilities was $70,000 and $72,000 for the three months ended March 31, 2023, and 2022, respectively, and this amount is included in operating activities in the statements of cash flows.

Right-of-use assets obtained in exchange for new operating lease liabilities were $nil and $nil for the three months ended March 31, 2023, and 2022, respectively.

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 6 - Commitments and Contingencies

A. Securities and Exchange Commission (“SEC”) Investigation 

As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.”

B. Litigation 

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. 

The Company is not subject to any litigation at the present time. 

C. Market Conditions – Coronavirus Pandemic 

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. While there are various uncertainties to navigate, the Company’s business activities are continuing. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. We cannot predict whether, when or the manner in which the conditions surrounding COVID-19 will change including the timing of lifting any restrictions or work from home arrangements.

The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others.

D. Environmental and Onshore Licensing Regulatory Matters 

The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings.

The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells.

As of March 31, 2023, and December 31, 2022, the Company accrued $nil and $nil for license regulatory matters.

E. Bank Guarantees 

As of March 31, 2023, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $1,042,000) and others (approximately $76,000) with respect to its drilling operation in an aggregate amount of approximately $1,118,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted.

F. Risks 

Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.

Foreign Currency Exchange Rate Risks. A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels (“NIS”). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar (“USD”), our primary reporting currency. During the period January 1, 2023 through March 31, 2023, the USD has fluctuated by approximately 2.7% against the NIS (the USD strengthened relative to the NIS). Also, during the period January 1, 2022 through December 31, 2022, the USD fluctuated by approximately 13.2% against the NIS (the USD strengthened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.

Interest Rate Risk. Our exposure to market risk relates to our cash and investments. We maintain an investment portfolio of short-term bank deposits and money market funds. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment. At March 31, 2023, we had cash, cash equivalents and short-term bank deposits of approximately $2,159,000. The weighted average annual interest rate related to our cash and cash equivalents for the three months ended March 31, 2023, exclusive of funds at US banks that earn no interest, was approximately 2.61%.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 7 - Subsequent Events

(i) Approximately $761,000 was collected through the Company’s DSPP program during the period April 1 through May 9, 2023.

XML

Accounting Policies, by Policy (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Net Loss per Share Data

A. Net Loss per Share Data 

Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share as the inclusion of 57,997,687 and 23,144,603 Common Stock equivalents in 2023, and 2022 respectively, would be anti-dilutive.

Use of Estimates

B. Use of Estimates 

The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods.

The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.

Oil and Gas Properties and Impairment

C. Oil and Gas Properties and Impairment 

The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method.

The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $45,615,000.

During the three months ended March 31, 2023, the Company recorded post-impairment charges of $45,000. During the three months ended March 31, 2022, the Company did not record any post-impairment charges.

Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $16,057,000 and $15,889,000 as of March 31, 2023 and December 31, 2022, respectively.

Fair Value Measurements

D. Fair Value Measurements 

The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At March 31, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.  

Stock-Based Compensation

E. Stock-Based Compensation 

ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

Warrants

F. Warrants 

In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity.

Related parties

G. Related parties 

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged.

Zion did not have any related party transactions for the periods covered in this report.

Recently Adopted Accounting Pronouncements

H. Recently Adopted Accounting Pronouncements 

In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

 In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. Zion adopted ASU 2021-08 in the first quarter of 2023. The adoption of this ASU did not have a material impact on our consolidated financial statements; the impact in future periods will be dependent upon the contract assets acquired and contract liabilities assumed in any future business combinations.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a roll forward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for roll forward information, which is effective for fiscal years beginning after December 15, 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

Other Recent Accounting Pronouncements

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow.

Depreciation and Accounting for Drilling Rig and Related Equipment

I. Depreciation and Accounting for Drilling Rig and Related Equipment 

On March 12, 2020, Zion entered into a Purchase and Sale Agreement with Central European Drilling kft (“CED”), a Hungarian corporation, to purchase an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, subject to acceptance testing and potential downward adjustment. On January 6, 2021, Zion completed its acceptance testing of the I-35 drilling rig and the Holdback Amount was remitted to Central European Drilling on January 8, 2021.

The full purchase price of the drilling rig was $5.6 million, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet.

In accordance with GAAP accounting rules, per the matching principle, monthly depreciation begins the month following when the asset is “placed in service.” The rig was placed in service in December 2020 with January 2021 representing the first month of depreciation. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion will depreciate the rig on a straight-line basis.

Zion uses the First In First Out (“FIFO”) method of accounting for the inventory spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed.

It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly.

See the table below for a reconciliation of the rig-related activity during the quarter ended March 31, 2023:

I-35 Drilling Rig & Associated Equipment:

	Three-month period ended March 31, 2023
	I-35 Drilling Rig			Rig Spare Parts			Other Drilling Assets			Total
	US$ thousands			US$ thousands			US$ thousands			US$ thousands
December 31, 2022		5,225			619			437			6,281
Asset Additions		-			-			-			-
Asset Depreciation		(159	)		-			(32	)		(191	)
Asset Disposals for Self-Consumption		-			(10	)		-			(10	)
March 31, 2023		5,066			609			405			6,080

XML

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of drilling rig & associated equipment [Abstract]

Schedule of drilling rig & associated equipment

	Three-month period ended March 31, 2023
	I-35 Drilling Rig			Rig Spare Parts			Other Drilling Assets			Total
	US$ thousands			US$ thousands			US$ thousands			US$ thousands
December 31, 2022		5,225			619			437			6,281
Asset Additions		-			-			-			-
Asset Depreciation		(159	)		-			(32	)		(191	)
Asset Disposals for Self-Consumption		-			(10	)		-			(10	)
March 31, 2023		5,066			609			405			6,080

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Stockholders' Equity (Tables) [Line Items]

Schedule of stock option transactions

	Number of shares			Weighted Average exercise price
				US$
Outstanding, December 31, 2022		26,391,250			0.30
Changes during 2023 to:
Granted to employees, officers, directors and others		200,000			0.06
Expired/Cancelled/Forfeited		-			-
Exercised		(125,000	)		0.06
Outstanding, March 31, 2023		26,466,250			0.30
Exercisable, March 31, 2023		14,901,250			0.40

Schedule of stock options outstanding

Shares underlying outstanding options (non-vested)								Shares underlying outstanding options (fully vested)
Range of exercise price		Number outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price		Range of exercise price		Number Outstanding		Weighted average remaining contractual life (years)		Weighted Average Exercise price
US$						US$		US$						US$
	0.15		6,410,000		9.05		0.15		0.01		10,000		0.62		0.01
	0.18		5,155,000		9.49		0.18		0.01		5,000		1.20		0.01
	—		—		—		—		0.01		20,000		3.17		0.01
	—		—		—		—		0.01		130,000		3.75		0.01
	—		—		—		—		0.01		50,000		3.76		0.01
	—		—		—		—		0.01		60,000		4.04		0.01
	—		—		—		—		0.01		200,000		4.13		0.01
	—		—		—		—		0.01		40,000		4.50		0.01
	—		—		—		—		0.01		70,000		4.75		0.01
	—		—		—		—		0.01		25,000		4.76		0.01
	—		—		—		—		0.01		30,000		4.91		0.01
	—		—		—		—		0.01		4,000		5.01		0.01
	—		—		—		—		0.01		25,000		5.77		0.01
	—		—		—		—		0.01		35,000		6.46		0.01
	—		—		—		—		0.01		150,000		6.63		0.01
	—		—		—		—		0.01		35,000		6.76		0.01
	—		—		—		—		0.01		75,000		7.76		0.01
	—		—		—		—		0.01		200,000		8.14		0.01
	—		—		—		—		0.01		300,000		8.29		0.01
	—		—		—		—		0.01		10,000		8.42		0.01
	—		—		—		—		0.01		500,000		8.76		0.01
	—		—		—		—		0.01		55,000		8.80		0.01
	—		—		—		—		0.01		960,000		9.04		0.01
	—		—		—		—		0.01		75,000		9.37		0.01
	—		—		—		—		0.01		10,000		9.42		0.01
	—		—		—		—		0.01		795,000		9.48		0.01
	—		—		—		—		0.01		25,000		9.76		0.01
	—		—		—		—		0.06		50,000		9.76		0.06
	—		—		—		—		0.14		240,000		8.80		0.14
	—		—		—		—		0.15		25,000		8.76		0.15
	—		—		—		—		0.15		3,200,000		9.00		0.15
	—		—		—		—		0.16		340,000		2.69		0.16
	—		—		—		—		0.16		75,000		6.69		0.16
	—		—		—		—		0.18		25,000		2.67		0.18
	—		—		—		—		0.24		25,000		9.34		0.24
	—		—		—		—		0.24		118,000		9.37		0.24
	—		—		—		—		0.25		50,000		8.42		0.25
	—		—		—		—		0.25		363,000		8.42		0.25
	—		—		—		—		0.28		25,000		2.42		0.28
	—		—		—		—		0.28		25,000		6.42		0.28
	—		—		—		—		0.29		25,000		4.20		0.29
	—		—		—		—		0.39		1,435,000		8.27		0.39
	—		—		—		—		0.59		1,400,000		4.13		0.59
	—		—		—		—		0.59		1,600,000		8.14		0.59
	—		—		—		—		0.92		350,000		3.76		0.92
	—		—		—		—		0.92		550,000		7.76		0.92
	—		—		—		—		1.33		25,000		0.07		1.33
	—		—		—		—		1.38		105,307		1.76		1.38
	—		—		—		—		1.67		405,943		1.51		1.67
	—		—		—		—		1.75		250,000		0.27		1.75
	—		—		—		—		1.78		25,000		1.43		1.78
	—		—		—		—		2.31		250,000		0.76		2.31
	—		—		—		—		4.15		25,000		1.26		4.15
	0.15-0.18		11,565,000				0.16		0.01-4.15		14,901,250				0.40

Schedule of the compensation cost of warrant and option issuances

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	415		214

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	2		1

For the three months ended March 31,
2023		2022
US$ thousands		US$ thousands
	—		7

Schedule of warrants description

		Period of Grant	US$		Expiration Date
ZNWAA Warrants	B,C,G	March 2013 – December 2014		2.00	January 31, 2024
ZNWAD Warrants	H	January 2015 – March 2016		1.00	May 02, 2023
ZNWAE Warrants	H	November 2016 – March 2017		1.00	May 01, 2023
ZNWAF Warrants	A,B,C	May 2017 – July 2017		1.00	August 14, 2023
ZNWAG Warrants	C,G	October 2017 – December 2017		1.00	January 08, 2024
ZNWAH Warrants	H	February 2018		5.00	April 19, 2023
ZNWAI Warrants	A,B,C	April 2018 – May 2018		3.00	June 29, 2023
ZNWAJ Warrants	B,C	August 2018 – September 2018		1.00	October 29, 2023
ZNWAK Warrants	H	December 2018 – January 2019		0.01	February 25, 2023
ZNWAL Warrants	C	July 2019 – August 2019		2.00	August 26, 2023
ZNWAM Warrants	D,I	January 2021 – March 2021		0.05	July 15, 2023
ZNWAN Warrants		May – June 2021		1.00	May 16, 2023
ZNWAO Warrants		June 2021		0.25	June 12, 2023
ZNWAQ Warrants	E,I	June 2021		0.05	July 6, 2023
ZNWAS Warrants	F	August 2021 – March 2022		0.25	December 31, 2025
ZNWAT Warrants	F	August – September 2022		0.25	December 31, 2025
ZNWAU Warrants	F	October – November 2022		0.25	December 31, 2025
ZNWAV Warrants	J	March 2023		0.05	June 28, 2023
ZNWAW Warrants	J	March – April 2023		0.05	July 13, 2023
ZNWAX Warrants	J	April 2023		0.05	July 31, 2023
ZNWAY Warrants	K	March – April 2023		0.05	Sept 10, 2023

* Zion’s ZNWAB Warrants expired on May 2, 2017, the ZNWAC Warrants expired on May 2, 2018, the ZNWAD Warrants expired on May 2, 2023, the ZNWAE Warrants expired on May 1, 2023, the ZNWAH Warrants expired on April 19, 2023, and the ZNWAK Warrants expired on February 25, 2023.

A	On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.
B	On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.
C	On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.
D	On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year.
E	These warrants were issued on May 5, 2022, and on May 17, 2022, the Company extended the expiration date of the Warrants by one (1) year.
F	These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.
G	On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year.
H	These warrants are now expired as of the report date.
I	The warrant exercise price was lowered to $0.05 on December 28, 2022.
J	On March 13, 2023, The Company announced a new Unit Offering, inclusive of three tranches of warrants (ZNWAV, ZNWAW and ZNWAX).

K The ZNWAY warrants are associated with Automatic Monthly Investments (“AMI”) connected with participation in the unit offering announced on March 13, 2023

Dividend Reinvestment And Stock Purchase Plan [Member]

Stockholders' Equity (Tables) [Line Items]

Schedule of warrants description

Warrants	Exercise Price		Warrant Termination Date	Outstanding Balance, 12/31/2022		Warrants Issued		Warrants Exercised			Warrants Expired			Outstanding Balance, 03/31/2023
ZNWAA	$	2.00	01/31/2024		1,498,804		-		-			-			1,498,804
ZNWAD	$	1.00	05/02/2023		243,853		-		-			-			243,853
ZNWAE	$	1.00	05/01/2023		2,144,099		-		-			-			2,144,099
ZNWAF	$	1.00	08/14/2023		359,435		-		-			-			359,435
ZNWAG	$	1.00	01/08/2024		240,068		-		-			-			240,068
ZNWAH	$	5.00	04/19/2023		372,400		-		-			-			372,400
ZNWAI	$	3.00	06/29/2023		640,710		-					-			640,710
ZNWAJ	$	1.00	10/29/2023		545,900		-		-			-			545,900
ZNWAK	$	0.01	02/25/2023		424,225		-		(9,050	)		(415,175	)		-
ZNWAL	$	2.00	08/26/2023		517,875		-		-			-			517,875
ZNWAM	$	0.05	07/15/2023		4,376,000		-		-			-			4,376,000
ZNWAN	$	1.00	05/16/2023		267,760		-		(50	)		-			267,710
ZNWAO	$	0.25	06/12/2023		174,660		-		-			-			174,660
ZNWAQ	$	0.05	07/06/2023		23,428,348		-		-			-			23,428,348
ZNWAV	$	0.05	06/28/2023		-		286,500		-			-			286,500
Outstanding warrants					35,234,137		286,500		(9,100	)		(415,175	)		35,096,362

Employees [Member]

Stockholders' Equity (Tables) [Line Items]

Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date	$	0.06		$	0.15
Dividend yields		—			—
Expected volatility		137	%		127%-133	%
Risk-free interest rates		3.85	%		1.37%-1.55	%
Expected lives (in years)		5.00			5.00-5.50
Weighted-average grant date fair value	$	0.06		$	0.13

	For the three months ended March 31,
	2023			2022
Weighted-average fair value of underlying stock at grant date		—		$	0.15
Dividend yields		—			—
Expected volatility		—	%		103	%
Risk-free interest rates		—	%		1.78	%
Expected lives (in years)		—			10
Weighted-average grant date fair value		—		$	0.14

XML

Unproved Oil and Gas Properties, Full Cost Method (Tables)

3 Months Ended

Mar. 31, 2023

Unproved Oil and Gas Properties, Full Cost Method [Abstract]

Schedule of unproved oil and gas properties

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		2,414		2,362
Capitalized salary costs		2,368		2,342
Capitalized interest costs		1,418		1,418
Legal and seismic costs, license fees and other preparation costs		9,818		9,728
Other costs		39		39
		16,057		15,889

Schedule of impairment of unproved oil and gas properties

	For the three months ended March 31,
	2023		2022
	US$ thousands		US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		11		-
Capitalized salary costs		-		-
Capitalized interest costs		-		-
Legal and seismic costs, license fees and other preparation costs		34		-
		45		-

Schedule of changes in Unproved oil and gas properties

	March 31, 2023			March 31, 2022
	US$ thousands			US$ thousands
Excluded from amortization base:
Drilling costs, and other operational related costs		63			628
Capitalized salary costs		26			52
Capitalized interest costs		-			-
Legal and seismic costs, license fees and other preparation costs		124			469
Other costs		-			-
Impairment of unproved oil and gas properties		(45	)		-
		*168			*1,149

* Inclusive of non-cash amounts of approximately $1,515,000, and $1,137,000 during the three months ended March 31, 2023, and 2022, respectively

XML

Right of Use Lease Assets and Lease Obligations (Tables)

3 Months Ended

Mar. 31, 2023

Right of Use Lease Assets and Lease Obligations [Abstract]

Schedule of operating lease assets and liabilities

	March 31, 2023		December 31, 2022
	US$ thousands		US$ thousands
Operating lease assets	$	135	$	202
Operating lease liabilities:
Current operating lease liabilities	$	125	$	196
Non-current operating lease liabilities	$	12	$	12
Total operating lease liabilities	$	137	$	208

Schedule of weighted average remaining lease term and weighted average discount rate for operating leases

	March 31, 2023
Weighted average remaining lease term (years)		0.75
Weighted average discount rate		4.9	%

Schedule of future minimum lease payments

	US$ thousands
2023		128
2024		11
2025		-
2026		-
Thereafter		-
Total undiscounted future minimum lease payments		139
Less: portion representing imputed interest		(2	)
Total undiscounted future minimum lease payments		137

XML

Nature of Operations, Basis of Presentation and Going Concern (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Nature of Operations, Basis of Presentation and Going Concern [Abstract]
Net loss	$ 2.2
Accumulated deficit	$ 281.0

XML

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Mar. 12, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock, par value (in Dollars per share)		$ 0.01		$ 0.01
Common stock equivalents (in Shares)		57,997,687	23,144,603
Other Asset Impairment Charges				$ 45,615,000
Post-impairment charges		$ 45,000
Capitalized exploration costs		$ 16,057,000		$ 15,889,000
Purchase price of drilling ring	$ 5,600,000
Allocated in spare parts	540,000
Allocated in additional separate assets.	$ 48,000
Life of the I-35 drilling rig		10 years
Purchase and Sale Agreement [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Purchase price					$ 5,600,000

XML

Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	$ 6,281
Asset Additions
Asset Depreciation	(191)
Asset Disposals for Self-Consumption	(10)
Balance Ending	6,080
I-35 Drilling Rig [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	5,225
Asset Additions
Asset Depreciation	(159)
Asset Disposals for Self-Consumption
Balance Ending	5,066
Rig Spare Parts [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	619
Asset Additions
Asset Depreciation
Asset Disposals for Self-Consumption	(10)
Balance Ending	609
Other Drilling Assets [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	437
Asset Additions
Asset Depreciation	(32)
Asset Disposals for Self-Consumption
Balance Ending	$ 405

XML

Stockholders' Equity (Details) - USD ($)		3 Months Ended
	Jun. 09, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 28, 2022	Dec. 14, 2022	May 17, 2022	Mar. 21, 2022	Sep. 15, 2020	Aug. 14, 2020	May 29, 2019	Dec. 04, 2018	Jan. 13, 2015
Stockholders' Equity (Details) [Line Items]
Common stock, par value	$ 0.01
Exercise price per unit		$ 0.25
Fair value of stock options granted (in Dollars)			$ 209,000
Unrecognized compensation cost (in Dollars)		$ 434,000
Warrants termination, description		An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017.
Price per share		$ 5
Common stock, par value		$ 0.01		$ 0.01
Offering cost, description		The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.
Raised amount (in Dollars)		$ 792,000	11,427,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit													$ 1
Share issued (in Shares)													1
Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares of common stock (in Shares)	38,000,000
Exercisable period	10 years
Dividend Reinvestment and Stock Purchase Plan [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description		The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00.
ZNWAB warrants [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description		As of May 2, 2017, any outstanding ZNWAB warrants expired.
ZNWAC warrants [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description		As of May 2, 2018, any outstanding ZNWAC warrants expired.
ZNWAD Warrants [Member]
Stockholders' Equity (Details) [Line Items]
Expiration date, description		On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.
ZNWAE warrants [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description		The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00.
Expiration date, description		On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit													$ 4
Share issued (in Shares)													3
ZNWAE warrants [Member]
Stockholders' Equity (Details) [Line Items]
Expiration date, description		On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.” The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00.
Znwaf [Member]
Stockholders' Equity (Details) [Line Items]
Expiration date, description		On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.
Common stock, par value		$ 5
ZNWAG [Member]
Stockholders' Equity (Details) [Line Items]
Offering cost, description		This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2024 at a revised per share exercise price of $.25. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023.
ZNHAH [Member]
Stockholders' Equity (Details) [Line Items]
Expiration date, description		The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2023 at a revised per share exercise price of $.05. On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to $0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” The warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00. On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” The warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25. On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired.  Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and are exercisable through July 6, 2023 at a revised per share exercise price of $.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continue to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 in equity issuance costs to an outside party related to this waiver program. On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of $.25. On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein. On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on September 30, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAT.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on December 31, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAU.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a program consisting of shares of stock to a participant. After conclusion of the program on June 16, 2023, the participant’s Plan account will be credited with the number of shares of the Company’s Common Stock that will be acquired. On March 13, 2023, Zion filed with the Securities and Exchange Commission an Amendment No. 2 to the Prospectus Supplement dated as of December 15, 2021 and accompanying base prospectus dated December 1, 2021 relating to the Company’s Dividend Reinvestment and Direct Stock Purchase Plan. This Amendment No. 2 to Prospectus Supplement amends the Prospectus Supplement. The Prospectus forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-261452), as amended, which was declared effective by the SEC on December 15, 2021. Amendment No. 2 - New Unit Option under the Unit Program Under our Plan, we provided a Unit Option under Amendment No. 2. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 2 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option had up to three tranches of investment, in which the second and third tranches were each subject to termination upon a total of $7,500,000 received from participants by the Company during the first or second tranche. The first tranche period began on March 13, 2023 and terminated on March 26, 2023. The second tranche began on March 27, 2023 and terminated on April 9, 2023 and the third tranche began on April 10, 2023 and terminated on April 27, 2023. The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional five hundred (500) shares of Common Stock at a per share exercise price of $0.05. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.05. The warrant shall have the Company notation of “ZNWAV” under the first tranche, “ZNWAW” under the second tranche and “ZNWAX” under the third tranche. The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month, received an additional fifty (50) warrants at an exercise price of $0.05 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program and shall have the Company notation of “ZNWAY.” Existing subscribers to the AMI are entitled to the additional fifty (50) warrants, if they purchase at least one (1) Unit during the Unit program. Plan participants, who enroll in the AMI at a minimum of $100 per month, will receive one hundred (100) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $250 per month, will receive two hundred and fifty (250) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $500 per month, will receive five hundred (500) ZNWAY warrants. The AMI program requires 90 days of participation to receive the ZNWAY warrants. Existing AMI participants are entitled to participate in this monthly program by increasing their monthly amount above the minimum $50.00 per month. The ZNWAV warrants became exercisable on March 31, 2023 and continue to be exercisable through June 28, 2023 at a per share exercise price of $0.05. The ZNWAW warrants became exercisable on April 14, 2023 and continue to be exercisable through July 13, 2023 at a per share exercise price of $0.05. The ZNWAX warrants became exercisable on May 2, 2023 and continue to be exercisable through July 31, 2023 at a per share exercise price of $0.05. The ZNWAY warrants will become exercisable on June 12, 2023 and will continue to be exercisable through September 10, 2023 at a per share exercise price of $0.05. For the three months ended March 31, 2023, and 2022, approximately $792,000 and $11,427,000 were raised under the DSPP program, respectively. The company raised approximately $761,000 from the period April 1, 2023 through May 9, 2023, under the DSPP program. The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.
Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit					$ 0.05
Expiration term						1 year	1 year	1 year	2 years		1 year	1 year
Six Senior Officers [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan (in Shares)		175,000
Exercise price per unit		$ 0.0615
Stock option plan, expiration date		January 4, 2032
Fair value of stock options granted (in Dollars)		$ 29,000
One Staff [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Stock option plan, expiration date		vested upon grant and are exercisable through January 4, 2033
One senior officer [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit		$ 0.01
Fair value of stock options granted (in Dollars)		$ 9,000
Shares purchased under option plan (in Shares)		25,000
Six Senior Officers One [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 22,000
Option to purchase shares of common stock (in Shares)		175,000
Exercise price per share		$ 0.1529
Six Senior Officers One [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan (in Shares)		1,600,000
Exercise price per unit		$ 0.1529
Fair value of stock options granted (in Dollars)		$ 1,500
One Senior Officers [Member] | 2011 Equity Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan (in Shares)		25,000
Exercise price per unit		$ 0.01
One Senior Officer [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 4,000
one senior officer and one staff [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 39,000
Option to purchase shares of common stock (in Shares)		300,000
Exercise price per share		$ 0.01
One Board [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Option to purchase shares of common stock (in Shares)		200,000
Exercise price per share		$ 0.01
Five Senior Officers [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 209,000
Seven Board [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 182,000
Seven Board [Member] | 2011 Non-Employee Directors Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Shares purchased under option plan (in Shares)		1,400,000
Exercise price per unit		$ 0.1529
Board [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)			182,000
Four Staff [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 23,000
Option to purchase shares of common stock (in Shares)		160,000
Exercise price per share		$ 0.01
Seven Staff [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Stock option plan, expiration date		January 17, 2032
Six Staff [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)			26,000
Six Staff [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 26,000
Option to purchase shares of common stock (in Shares)		200,000
Exercise price per share		$ 0.14
Two Consultants [Member] | Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)		$ 5,000
Option to purchase shares of common stock (in Shares)		40,000
Exercise price per share		$ 0.14
Two Zero Two One Omnibus Incentive Stock Option Plan [Member]
Stockholders' Equity (Details) [Line Items]
Fair value of stock options granted (in Dollars)			$ 5,000
New Unit Program [Member] | Znwaf [Member]
Stockholders' Equity (Details) [Line Items]
Exercise price per unit										$ 1
Unit Option Program [Member] | ZNWAK [Member]
Stockholders' Equity (Details) [Line Items]
Warrants termination, description		The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) is comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01.
Expiration date, description		The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023.
Unit Option Program [Member] | Znwaf [Member]
Stockholders' Equity (Details) [Line Items]
New unit program, description		This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.”
Amended and Restated Certificate of Incorporation [Member] | Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Increase in shares authorized (in Shares)	400,000,000
Amended and Restated Certificate of Incorporation [Member] | Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Increase in shares authorized (in Shares)	800,000,000

XML

Stockholders' Equity (Details) - Schedule of stock option transactions - Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Stockholders' Equity (Details) - Schedule of stock option transactions [Line Items]
Number of shares, Outstanding, Begining | shares	26,391,250
Weighted Average exercise price, Outstanding, Begining | $ / shares	$ 0.3
Number of shares, Granted to employees, officers, directors and others | shares	200,000
Weighted Average exercise price, Granted to employees, officers, directors and others | $ / shares	$ 0.06
Number of shares, Expired/Cancelled/Forfeited | shares
Weighted Average exercise price, Expired/Cancelled/Forfeited | $ / shares
Number of shares, Exercised | shares	(125,000)
Weighted Average exercise price, Exercised | $ / shares	$ 0.06
Number of shares, Outstanding, Ending | shares	26,466,250
Weighted Average exercise price, Outstanding, Ending | $ / shares	$ 0.3
Number of shares, Exercisable | shares	14,901,250
Weighted Average exercise price, Exercisable | $ / shares	$ 0.4

XML

Stockholders' Equity (Details) - Schedule of stock options outstanding	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares	11,565,000
Weighted Average Exercise price	$ 0.16
Non-vested [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.15
Non-vested [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.18
Non-vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	6,410,000
Weighted average remaining contractual life (years)	9 years 18 days
Weighted Average Exercise price	$ 0.15
Non-vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	5,155,000
Weighted average remaining contractual life (years)	9 years 5 months 26 days
Weighted Average Exercise price	$ 0.18
Non-vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Scenario Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares	14,901,250
Weighted Average Exercise price	$ 0.4
Vested [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.01
Vested [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	4.15
Vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	7 months 13 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	5,000
Weighted average remaining contractual life (years)	1 year 2 months 12 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	20,000
Weighted average remaining contractual life (years)	3 years 2 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	130,000
Weighted average remaining contractual life (years)	3 years 9 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	3 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	60,000
Weighted average remaining contractual life (years)	4 years 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	4 years 1 month 17 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	40,000
Weighted average remaining contractual life (years)	4 years 6 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	70,000
Weighted average remaining contractual life (years)	4 years 9 months
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	30,000
Weighted average remaining contractual life (years)	4 years 10 months 28 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	4,000
Weighted average remaining contractual life (years)	5 years 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Scenario Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	6 years 5 months 15 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	150,000
Weighted average remaining contractual life (years)	6 years 7 months 17 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	6 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	7 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	8 years 1 month 20 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	300,000
Weighted average remaining contractual life (years)	8 years 3 months 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	8 years 5 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	500,000
Weighted average remaining contractual life (years)	8 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	55,000
Weighted average remaining contractual life (years)	8 years 9 months 18 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	960,000
Weighted average remaining contractual life (years)	9 years 14 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	9 years 4 months 13 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 5 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	795,000
Weighted average remaining contractual life (years)	9 years 5 months 23 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.06
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	9 years 9 months 3 days
Weighted Average Exercise price	$ 0.06
Vested [Member] | Ranges Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.14
Number Outstanding (in Shares) | shares	240,000
Weighted average remaining contractual life (years)	8 years 9 months 18 days
Weighted Average Exercise price	$ 0.14
Vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	8 years 9 months 3 days
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	3,200,000
Weighted average remaining contractual life (years)	9 years
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	340,000
Weighted average remaining contractual life (years)	2 years 8 months 8 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	6 years 8 months 8 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 8 months 1 day
Weighted Average Exercise price	$ 0.18
Vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 4 months 2 days
Weighted Average Exercise price	$ 0.24
Vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	118,000
Weighted average remaining contractual life (years)	9 years 4 months 13 days
Weighted Average Exercise price	$ 0.24
Vested [Member] | Ranges Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	8 years 5 months 1 day
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	363,000
Weighted average remaining contractual life (years)	8 years 5 months 1 day
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 5 months 1 day
Weighted Average Exercise price	$ 0.28
Vested [Member] | Ranges Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	6 years 5 months 1 day
Weighted Average Exercise price	$ 0.28
Vested [Member] | Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.29
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 2 months 12 days
Weighted Average Exercise price	$ 0.29
Vested [Member] | Ranges Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number Outstanding (in Shares) | shares	1,435,000
Weighted average remaining contractual life (years)	8 years 3 months 7 days
Weighted Average Exercise price	$ 0.39
Vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,400,000
Weighted average remaining contractual life (years)	4 years 1 month 17 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Range Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,600,000
Weighted average remaining contractual life (years)	8 years 1 month 20 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Range Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	350,000
Weighted average remaining contractual life (years)	3 years 9 months 3 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Range Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	550,000
Weighted average remaining contractual life (years)	7 years 9 months 3 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Range Fourty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.33
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	25 days
Weighted Average Exercise price	$ 1.33
Vested [Member] | Ranges Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.38
Number Outstanding (in Shares) | shares	105,307
Weighted average remaining contractual life (years)	1 year 9 months 3 days
Weighted Average Exercise price	$ 1.38
Vested [Member] | Ranges Fourty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.67
Number Outstanding (in Shares) | shares	405,943
Weighted average remaining contractual life (years)	1 year 6 months 3 days
Weighted Average Exercise price	$ 1.67
Vested [Member] | Ranges Fifty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.75
Number Outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	3 months 7 days
Weighted Average Exercise price	$ 1.75
Vested [Member] | Ranges Fifty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.78
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 5 months 4 days
Weighted Average Exercise price	$ 1.78
Vested [Member] | Ranges Fifty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 2.31
Number Outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	9 months 3 days
Weighted Average Exercise price	$ 2.31
Vested [Member] | Ranges Fifty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 4.15
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 3 months 3 days
Weighted Average Exercise price	$ 4.15

XML

Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee [Member]
Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.15
Dividend yields
Weighted-average grant date fair value (in Dollars per share)	$ 0.13
Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.15
Dividend yields
Expected volatility	103.00%
Risk-free interest rates	1.78%
Expected life (in years)	10 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.14
Minimum [Member] | Employee [Member]
Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.06
Dividend yields
Expected volatility	137.00%	127.00%
Risk-free interest rates	3.85%	1.37%
Expected life (in years)	5 years	5 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.06
Minimum [Member] | Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)
Dividend yields
Expected volatility
Risk-free interest rates
Expected life (in years)
Weighted-average grant date fair value (in Dollars per share)
Maximum [Member] | Employee [Member]
Stockholders' Equity (Details) - Schedule of assumptions used to estimate fair value of warrants granted using black-scholes option pricing model [Line Items]
Expected volatility		133.00%
Risk-free interest rates		1.55%
Expected life (in years)		5 years 6 months

XML

Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employees And Directors [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	$ 415	$ 214
Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	2	1
Non-Employees and Capitalized Unproved Oil & Gas Properties [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances		$ 7

XML

Stockholders' Equity (Details) - Schedule of warrants transactions - $ / shares	3 Months Ended
	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Outstanding warrants, Beginning Balance			35,234,137
Warrants Issued	286,500
Warrants Exercised	(9,100)
Warrants Expired	(415,175)
Outstanding warrants, Ending Balance		35,096,362
ZNWAA Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 2
Warrant Termination Date	Jan. 31, 2024
Outstanding warrants, Beginning Balance			1,498,804
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		1,498,804
ZNWAD Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	May 02, 2023
Outstanding warrants, Beginning Balance			243,853
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		243,853
ZNWAE Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	May 01, 2023
Outstanding warrants, Beginning Balance			2,144,099
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		2,144,099
ZNWAF [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	Aug. 14, 2023
Outstanding warrants, Beginning Balance			359,435
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		359,435
ZNWAG [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	Jan. 08, 2024
Outstanding warrants, Beginning Balance			240,068
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		240,068
ZNWAH [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 5
Warrant Termination Date	Apr. 19, 2023
Outstanding warrants, Beginning Balance			372,400
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		372,400
ZNWAI Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 3
Warrant Termination Date	Jun. 29, 2023
Outstanding warrants, Beginning Balance			640,710
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		640,710
ZNWAJ Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	Oct. 29, 2023
Outstanding warrants, Beginning Balance			545,900
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		545,900
ZNWAK Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 0.01
Warrant Termination Date	Feb. 25, 2023
Outstanding warrants, Beginning Balance			424,225
Warrants Issued
Warrants Exercised	(9,050)
Warrants Expired	(415,175)
ZNWAL Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 2
Warrant Termination Date	Aug. 26, 2023
Outstanding warrants, Beginning Balance			517,875
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		517,875
ZNWAM Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 0.05
Warrant Termination Date	Jul. 15, 2023
Outstanding warrants, Beginning Balance			4,376,000
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		4,376,000
ZNWAN Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	May 16, 2023
Outstanding warrants, Beginning Balance			267,760
Warrants Issued
Warrants Exercised	(50)
Warrants Expired
Outstanding warrants, Ending Balance		267,710
ZNWAO Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 0.25
Warrant Termination Date	Jun. 12, 2023
Outstanding warrants, Beginning Balance			174,660
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		174,660
ZNWAQ Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 0.05
Warrant Termination Date	Jul. 06, 2023
Outstanding warrants, Beginning Balance			23,428,348
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance		23,428,348
ZNWAV Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	$ 0.05
Warrant Termination Date	Jun. 28, 2023
Warrants Issued	286,500
Outstanding warrants, Ending Balance		286,500

XML

Stockholders' Equity (Details) - Schedule of warrants description - Investor [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares
ZNWAA Warrants [Member]
Class of Warrant or Right [Line Items]
Name	B,C,G	[1],[2],[3],[4]
Period of Grant	March 2013 – December 2014	[1],[2],[3],[4]
Exercise Price	$ 2	[1],[2],[3],[4]
Expiration Date	January 31, 2024	[1],[2],[3],[4]
ZNWAD Warrants [Member]
Class of Warrant or Right [Line Items]
Name	H	[4],[5]
Period of Grant	January 2015 – March 2016	[4],[5]
Exercise Price	$ 1	[4],[5]
Expiration Date	May 02, 2023	[4],[5]
ZNWAE Warrants [Member]
Class of Warrant or Right [Line Items]
Name	H	[4],[5]
Period of Grant	November 2016 – March 2017	[4],[5]
Exercise Price	$ 1	[4],[5]
Expiration Date	May 01, 2023	[4],[5]
ZNWAF Warrants [Member]
Class of Warrant or Right [Line Items]
Name	A,B,C	[2],[3],[4],[6]
Period of Grant	May 2017 – July 2017	[2],[3],[4],[6]
Exercise Price	$ 1	[2],[3],[4],[6]
Expiration Date	August 14, 2023	[2],[3],[4],[6]
ZNWAG Warrants [Member]
Class of Warrant or Right [Line Items]
Name	C,G	[1],[3],[4]
Period of Grant	October 2017 – December 2017	[1],[3],[4]
Exercise Price	$ 1	[1],[3],[4]
Expiration Date	January 08, 2024	[1],[3],[4]
ZNWAH Warrants [Member]
Class of Warrant or Right [Line Items]
Name	H	[4],[5]
Period of Grant	February 2018	[4],[5]
Exercise Price	$ 5	[4],[5]
Expiration Date	April 19, 2023	[4],[5]
ZNWAI Warrants [Member]
Class of Warrant or Right [Line Items]
Name	A,B,C	[2],[3],[4],[6]
Period of Grant	April 2018 – May 2018	[2],[3],[4],[6]
Exercise Price	$ 3	[2],[3],[4],[6]
Expiration Date	June 29, 2023	[2],[3],[4],[6]
ZNWAJ Warrants [Member]
Class of Warrant or Right [Line Items]
Name	B,C	[2],[3],[4]
Period of Grant	August 2018 – September 2018	[2],[3],[4]
Exercise Price	$ 1	[2],[3],[4]
Expiration Date	October 29, 2023	[2],[3],[4]
ZNWAK Warrants [Member]
Class of Warrant or Right [Line Items]
Name	H	[4],[5]
Period of Grant	December 2018 – January 2019	[4],[5]
Exercise Price	$ 0.01	[4],[5]
Expiration Date	February 25, 2023	[4],[5]
ZNWAL Warrants [Member]
Class of Warrant or Right [Line Items]
Name	C	[3],[4]
Period of Grant	July 2019 – August 2019	[3],[4]
Exercise Price	$ 2	[3],[4]
Expiration Date	August 26, 2023	[3],[4]
ZNWAM Warrants [Member]
Class of Warrant or Right [Line Items]
Name	D,I	[4],[7],[8]
Period of Grant	January 2021 – March 2021	[4],[7],[8]
Exercise Price	$ 0.05	[4],[7],[8]
Expiration Date	July 15, 2023	[4],[7],[8]
ZNWAN Warrants [Member]
Class of Warrant or Right [Line Items]
Period of Grant	May – June 2021
Exercise Price	$ 1
Expiration Date	May 16, 2023
ZNWAO Warrants [Member]
Class of Warrant or Right [Line Items]
Period of Grant	June 2021
Exercise Price	$ 0.25
Expiration Date	June 12, 2023
ZNWAQ Warrants [Member]
Class of Warrant or Right [Line Items]
Name	E,I	[4],[8],[9]
Period of Grant	June 2021	[4],[8],[9]
Exercise Price	$ 0.05	[4],[8],[9]
Expiration Date	July 6, 2023	[4],[8],[9]
ZNWAS Warrants [Member]
Class of Warrant or Right [Line Items]
Name	F	[4],[10]
Period of Grant	August 2021 – March 2022	[4],[10]
Exercise Price	$ 0.25	[4],[10]
Expiration Date	December 31, 2025	[4],[10]
ZNWAT Warrants [Member]
Class of Warrant or Right [Line Items]
Name	F	[4],[10]
Period of Grant	August – September 2022	[4],[10]
Exercise Price	$ 0.25	[4],[10]
Expiration Date	December 31, 2025	[4],[10]
ZNWAU Warrants [Member]
Class of Warrant or Right [Line Items]
Name	F	[4],[10]
Period of Grant	October – November 2022	[4],[10]
Exercise Price	$ 0.25	[4],[10]
Expiration Date	December 31, 2025	[4],[10]
ZNWAV Warrants [Member]
Class of Warrant or Right [Line Items]
Name	J	[4],[11]
Period of Grant	March 2023	[4],[11]
Exercise Price	$ 0.05	[4],[11]
Expiration Date	June 28, 2023	[4],[11]
ZNWAW Warrants [Member]
Class of Warrant or Right [Line Items]
Name	J	[4],[11]
Period of Grant	March – April 2023	[4],[11]
Exercise Price	$ 0.05	[4],[11]
Expiration Date	July 13, 2023	[4],[11]
ZNWAX Warrants [Member]
Class of Warrant or Right [Line Items]
Name	J	[4],[11]
Period of Grant	April 2023	[4],[11]
Exercise Price	$ 0.05	[4],[11]
Expiration Date	July 31, 2023	[4],[11]
ZNWAY Warrants [Member]
Class of Warrant or Right [Line Items]
Name	K	[4],[12]
Period of Grant	March – April 2023	[4],[12]
Exercise Price	$ 0.05	[4],[12]
Expiration Date	Sept 10, 2023	[4],[12]

[1] On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year.

[2] On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.

[3] On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.

[4] Zion’s ZNWAB Warrants expired on May 2, 2017, the ZNWAC Warrants expired on May 2, 2018, the ZNWAD Warrants expired on May 2, 2023, the ZNWAE Warrants expired on May 1, 2023, the ZNWAH Warrants expired on April 19, 2023, and the ZNWAK Warrants expired on February 25, 2023.

[5] These warrants are now expired as of the report date.

[6] On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year.

[7] On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year.

[8] The warrant exercise price was lowered to $0.05 on December 28, 2022.

[9] These warrants were issued on May 5, 2022, and on May 17, 2022, the Company extended the expiration date of the Warrants by one (1) year.

[10] These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.

[11] On March 13, 2023, The Company announced a new Unit Offering, inclusive of three tranches of warrants (ZNWAV, ZNWAW and ZNWAX).

[12] The ZNWAY warrants are associated with Automatic Monthly Investments (“AMI”) connected with participation in the unit offering announced on March 13, 2023

XML

Unproved Oil and Gas Properties, Full Cost Method (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Oil and Gas Property [Abstract]
Inclusive of non-cash amounts	$ 1,515,000	$ 1,137,000

XML

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of unproved oil and gas properties - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Schedule of unproved oil and gas properties [Abstract]
Drilling costs, and other operational related costs	$ 2,414	$ 2,362
Capitalized salary costs	2,368	2,342
Capitalized interest costs	1,418	1,418
Legal and seismic costs, license fees and other preparation costs	9,818	9,728
Other costs	39	39
Total unproved oil and gas properties	$ 16,057	$ 15,889

XML

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of impairment of unproved oil and gas properties - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Schedule of impairment of unproved oil and gas properties [Abstract]
Drilling costs, and other operational related costs	$ 11
Capitalized salary costs
Capitalized interest costs
Legal and seismic costs, license fees and other preparation costs	34
Total unproved oil and gas properties	$ 45

XML

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of changes in Unproved oil and gas properties - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Schedule of changes in Unproved oil and gas properties [Abstract]
Drilling costs, and other operational related costs		$ 63	$ 628
Capitalized salary costs		26	52
Capitalized interest costs
Legal and seismic costs, license fees and other preparation costs		124	469
Other costs
Impairment of unproved oil and gas properties		(45)
Total unproved oil and gas properties	[1]	$ 168	$ 1,149

[1] Inclusive of non-cash amounts of approximately $1,515,000, and $1,137,000 during the three months ended March 31, 2023, and 2022, respectively

XML

Right of Use Lease Assets and Lease Obligations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Right of Use Leases Assets and Leases Obligations [Abstract]
Operating lease costs	$ 69,000	$ 68,000
Operating lease liabilities	70,000	72,000
Right-of-use assets obtained in exchange for new operating lease liabilities

XML

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities - Rights use of assets [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities [Line Items]
Operating lease assets	$ 135	$ 202
Operating lease liabilities:
Current operating lease liabilities	125	196
Non-current operating lease liabilities	12	12
Total operating lease liabilities	$ 137	$ 208

XML

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	Mar. 31, 2023
Schedule Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate For Operating Leases [Abstract]
Weighted average remaining lease term (years)	9 months
Weighted average discount rate	4.90%

XML

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of future minimum lease payments $ in Thousands	Mar. 31, 2023 USD ($)
Schedule Of Future Minimum Lease Payments Under Non Cancellable Operating Leases [Abstract]
2023	$ 128
2024	11
2025
2026
Thereafter
Total undiscounted future minimum lease payments	139
Less: portion representing imputed interest	(2)
Total undiscounted future minimum lease payments	$ 137

XML

Commitments and Contingencies (Details) - USD ($)		3 Months Ended	12 Months Ended
	Apr. 05, 2023	Mar. 31, 2023	Dec. 31, 2022
Commitments and Contingencies (Details) [Line Items]
Accrued license costs
Bank guarantees to government		$ 1,042,000
Aggregate guarantee amount		$ 1,118,000
Risk percentage		2.70%	13.20%
Short-term bank deposits		$ 2,159,000
Interest rate		2.61%
David McDavid Plano Lincoln Mercury [Member]
Commitments and Contingencies (Details) [Line Items]
Lessor agreement description	In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells.
Product Concentration Risk [Member]
Commitments and Contingencies (Details) [Line Items]
Bank guarantees to others		$ 76,000
Subsequent Event [Member] | Second Renewal Letter [Member]
Commitments and Contingencies (Details) [Line Items]
Letter agreement description	the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.

XML

Subsequent Events (Details)	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Event, Description	Approximately $761,000 was collected through the Company’s DSPP program during the period April 1 through May 9, 2023.